Podcasts about Hodgkin

This week: The crew kicks off with some genuinely great news: Gary Chalk (the voice of Optimus Primal!) has beaten stage four Hodgkin's lymphoma and is in full remission. From there it's all Transformers chaos — the Generation Selects Monstrucker reveal has everyone hyped (Slog's alt mode is literally just a triceratops standing up, and somehow that's perfect), while 2026 product listings bring a BotCon-referencing Megazarak redeco, an Earthrise Autobot 3-pack with finally-opaque Datsun plastics, and a Walmart Energon capsule that the crew suspects will be drowning in clear plastic. In-hand photos of the Stranger Things crossover Frequency impress even the hosts who've never watched the show. All that and more on this week's Radio Free Cybertron!

This week: The crew kicks off with some genuinely great news: Gary Chalk (the voice of Optimus Primal!) has beaten stage four Hodgkin's lymphoma and is in full remission. From there it's all Transformers chaos — the Generation Selects Monstrucker reveal has everyone hyped (Slog's alt mode is literally just a triceratops standing up, and somehow that's perfect), while 2026 product listings bring a BotCon-referencing Megazarak redeco, an Earthrise Autobot 3-pack with finally-opaque Datsun plastics, and a Walmart Energon capsule that the crew suspects will be drowning in clear plastic. In-hand photos of the Stranger Things crossover Frequency impress even the hosts who've never watched the show. All that and more on this week's Radio Free Cybertron!

It's time for a round up on Roundup, or more accurately, on glyphosate. We're discussing the latest on America's favorite herbicide/pesticide. Most of our corn, soybeans, and cotton being grown in the US use the product and even many have been planting so-called "Roundup Ready" genetically engineered glyphosate-tolerant crops were introduced in 1996. Since glyphosate has been linked to non-Hodgkin lymphoma in thousands of lawsuits, we're questioning what can we do to counteract the toxic load? Is there any way to escape it? Is there anything we can do to mitigate it?  We think you'll find some hope and actionable take aways when you listen to the BrainStim gang discuss this crucial health topic. www.invisionchiropractic.com/schedule 

Glyphosate, the active ingredient in Roundup and the most widely used herbicide in the US, has surged back into public debate. This episode provides the background information you need to know, including how this chemical works, what it does to soil health and the gut microbiome, and its contested link to non-Hodgkin lymphoma.Jeff also unpacks the current legal and political landscape: the Supreme Court case that could shield Bayer-Monsanto from future cancer lawsuits, the Trump administration's executive action expanding agricultural chemical use, and what a real transition away from chemical-dependent farming might actually require.This show is made possible by: Stemregen: Get 20% off your first order at stemregen.co/commune with the code COMMUNEPOD CBDistillery: Go to CBDistillery.com and use code COMMUNE for 25% off. Vivobarefoot: Try Vivobarefoot risk-free with a 100-day return guarantee, and get 15% off your order at vivobarefoot.com/commune. LMNT: Get a free 8-count Sample Pack of LMNT's most popular drink mix flavors with any purchase at ⁠drinklmnt.com/commune⁠.

"Because the premise of immune checkpoint blockade centers around elevating the immune function, we should always take a great deal of caution around those patients who have high immune risks. Those include patients with autoimmune disorders. That's one of our biggest questions that we ask, usually every consult that we're seeing with solid tumor. 'Do you have any history of autoimmune disorders? Tell me a little bit more about it. Is it being treated? What are your symptoms like?' And then also patients who have undergone organ transplants. Now, interestingly, this does include stem cell transplants," Kelsey Finch, PharmD, BCOP, oncology pharmacist practitioner at Columbus Regional Health in Indiana, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about checkpoint inhibitors. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 20, 2027. Kelsey Finch has disclosed a speakers bureau relationship with AstraZeneca. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to checkpoint inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 273: Updates in Chemotherapy and Immunotherapy Episode 174: Administer Pembrolizumab Immunotherapy With Confidence Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment ONS Voice articles: Here's Why Oncology Nurses Are Pivotal in Managing Immune-Related Adverse Events Make Subcutaneous Administration More Comfortable for Your Patients Nursing Considerations for ICI-Related Myocarditis Oncology Nurses Navigate the Changing Landscape of Immuno-Oncology Postdischarge ICI Patient Education Eliminates Hospital Readmissions Shorter Administration Times Still Require High-Acuity Care ONS Voice oncology drug reference sheets: Dostarlimab-Gxly Nivolumab and Hyaluronidase-Nvhy Nivolumab and Relatlimab-Rmbw Pembrolizumab and Berahyaluronidase Alfa-Pmph Retifanlimab-Dlwr Toripalimab-Tpzi ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing articles: Immune Checkpoint Inhibitor–Related Myocarditis: Recognition, Surveillance, and Management Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients Triple M Syndrome: Implications for Hematology-Oncology Advanced Practice Providers ONS Huddle Cards: Checkpoint Inhibitors Immunotherapy ONS Learning Libraries: Genomics and Precision Oncology Learning Library Immuno-Oncology Learning Library Drugs@FDA package inserts National Comprehensive Cancer Network homepage OncoLink: All About Immunotherapy To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Before immune checkpoint blockade, the two-year overall survival rate in metastatic melanoma was hovering around 10%. After these agents came to market, depending on the trial and the agents used, that number actually increased to about 50%–65%. So, five times the amount of patients were actually living at the two-year mark. Not surprisingly, studies then exploded across several tumor types, leading to approvals in all sorts of cancers, mostly in the solid tumor. But there are a couple hematologic as well. Lung cancer, kidney cancer, head and neck, Hodgkin lymphoma, hepatocellular, the list goes on. So, it's really just transforming the stage IV setting across all tumors, specifically from uniformly fatal prognosis to one where durable responses and long-term survival is also possible." TS 3:03 "There are four different mechanisms officially being used in therapies that are approved by the U.S. Food and Drug Administration (FDA). Those are cytotoxic T-lymphocyte–associated protein 4, programmed cell death protein 1, and programmed cell death ligand 1, which I'm counting as two different mechanisms, even though they somewhat work together. And lymphocyte-activation gene 3 is the fourth one that's in there. So, all these mechanisms impact the T cell in our immune system. The T cell is traditionally responsible for protecting our body from harmful things like bacteria, viruses, and cancer. When the tumor binds to cytotoxic T-lymphocyte–associated protein 4 receptors, that happens on the T cell itself. And that inhibits the activation of the T cells, essentially allowing that tumor to then live. So when developing medications that block this receptor, they noted an added benefit that it actually increased the T-cell proliferation as well as keeping that T cell active. So not only are we not blocking the T cells, we're making them more productive." TS 5:38  "If you have a chance of any sort of tissue rejection, specifically with allogeneic stem cell transplants or where we see that focusing on it, there's a little bit of controversy, mixed bag on opinions as far as autologous stem cell transplants. But it's best to at least exercise a little bit of caution. If they have a chance of organ rejection, is that worth the risk of the therapy that we're looking to give? And then, patients with HIV, any sort of immunologic concerns at baseline that we could potentially worsen." TS 14:37 "As a rule of thumb, with immune checkpoint blockade, regardless of what mechanism you're looking at, if something in your body can get inflamed, that can wind up as an adverse event. So, whenever I talk to my patients, the key word is anything ending in '-itis.' ... The most common adverse events that we end up seeing are dermatitis and hypothyroidism. Immune checkpoint blockade can cause both hyper- and hypothyroidism. Very often, we actually start in the hyper- and then end up, for lack of better words, burning out the thyroid, ultimately leading to a sustained hypothyroidism." TS 18:34 "The half-life of immune checkpoint inhibitors is usually around 30 days, meaning that once these agents are given, the drug will be in the patient's system for up to five months. Specifically, it will probably build month to month, so often we don't even see a lot of our adverse events until month three or four. Usually, when we're that far into treatment, we're not looking for new adverse events in things like chemotherapy. But these drugs do build over time." TS 24:28 "As far as safe handling is concerned, these agents are not chemotherapy. That makes drug compounding and administration pretty straightforward. When looking at the follow-up care, the most important thing, in my opinion, is to engage in meaningful dialogue with your patients. A lot of the side effects can be nonspecific. So, really listening to the patient and evaluating changes in their lifestyle, I think it'll get you far. We usually hark in on the new, worsening, or persistent whenever we're talking to patients because they'll be looking for things as well. So, just having a dialogue of how their life has changed can certainly help." TS 26:17

This Day in Legal History: Aaron Burr Arrested (But Not For That)On February 18, 1807, former Vice President Aaron Burr was arrested in the Mississippi Territory on charges of treason against the United States. Once one of the most powerful men in the young republic, Burr had fallen from political grace after killing Alexander Hamilton in a duel and drifting to the margins of national life. Federal authorities accused him of plotting to carve out an independent nation in the western territories, possibly including lands belonging to Spain. The allegations sparked fear that the fragile Union could splinter only decades after independence.Later that year, Burr stood trial in Richmond, Virginia, before Chief Justice John Marshall, who was riding circuit. The case quickly became a constitutional showdown between executive power and judicial restraint. President Thomas Jefferson strongly supported the prosecution, but Marshall insisted that the Constitution's Treason Clause be applied strictly. The Constitution requires proof of an “overt act” of levying war against the United States, not merely evidence of intent or conspiracy.Marshall ruled that prosecutors had failed to present sufficient proof that Burr had committed such an overt act. As a result, the jury acquitted him. The decision established an enduring precedent that treason must be narrowly defined and carefully proven. By demanding clear evidence of action rather than suspicion or political hostility, the court reinforced limits on the government's power to punish alleged disloyalty. Burr's trial remains one of the earliest and most significant tests of constitutional safeguards in American legal history.Bayer AG and its Monsanto subsidiary have proposed a $7.25 billion nationwide class settlement to resolve current and future claims that Roundup exposure caused non-Hodgkin lymphoma. Filed in Missouri state court, the agreement would run for up to 21 years and provide capped, declining annual payments. People diagnosed before or within 16 years after final court approval could seek compensation through the program. The settlement must still receive judicial approval.The proposal is part of a broader strategy tied to the U.S. Supreme Court's pending review of Durnell v. Monsanto, which could determine whether federal pesticide labeling law blocks certain state failure-to-warn claims. Bayer has indicated that a favorable ruling could significantly limit future lawsuits, while the class program is designed to address claims regardless of the Court's decision. Plaintiffs' attorneys say the deal would cover both occupational and residential exposure and protect the rights of future claimants, while allowing individuals to opt out and pursue separate suits.Roundup litigation has generated tens of thousands of cases, with more than 40,000 already pending or subject to tolling agreements. Bayer inherited the legal challenges after acquiring Monsanto in 2018, and the ongoing litigation has weighed heavily on the company financially and reputationally. Previous jury verdicts have resulted in multibillion-dollar awards, some later reduced on appeal or by judges. The new proposal would replace an earlier settlement effort that collapsed in 2020 and aims to create a longer-term, more predictable compensation system.Bayer AG Unveils $7.3B Deal For Roundup Users - Law360Bayer proposes $7.25 billion plan to settle Roundup cancer cases | ReutersA Seattle federal jury found inventor Leigh Rothschild, several of his patent-holding companies, and his former attorney liable for violating Washington's anti-patent trolling law after asserting patent infringement claims against Valve Corp. Jurors concluded the defendants acted in bad faith under the Washington Patent Troll Prevention Act and also violated the state's consumer protection statute. Valve was awarded $22,092 in statutory damages.The jury also determined that Rothschild and his companies breached a 2016 global settlement and licensing agreement with Valve. Under that agreement, Valve paid $130,000 for rights to certain patents in exchange for a promise not to sue over them. Despite that covenant, Rothschild's entities later filed a 2022 infringement lawsuit and sent a 2023 letter threatening additional litigation. The jury awarded Valve $130,000 for the first breach and $1 for the second, finding no valid justification for repudiating the agreement.In addition, jurors ruled that one asserted patent claim was invalid because it would have been obvious to a skilled professional at the time of filing. The dispute stemmed from Valve's 2023 lawsuit accusing Rothschild of repeatedly pursuing claims covered by the prior settlement. The defense argued any mistakes were unintentional and not profit-driven, but the jury sided with Valve after a four-day trial.The case also involved procedural controversies, including sanctions over delayed financial disclosures and allegations that a defense filing contained fabricated quotations and citations generated by artificial intelligence. Post-trial motions are expected as the defense challenges aspects of the verdict.Valve Jury Says Rothschild, Atty Broke Anti-Patent Troll Law - Law360Beginning July 1, 2026, new federal limits will cap loans for professional degree students at $50,000 per year and $200,000 total, significantly changing how aspiring lawyers finance law school. Administrators and financial aid experts warn that the cap may push students to rely on private loans, which often carry higher interest rates and fewer protections. Unlike federal loans, private loans are generally not eligible for Public Service Loan Forgiveness, making them riskier for students planning lower-paying public interest careers.Some admitted students are already reconsidering their options, choosing less expensive schools or withdrawing altogether after calculating potential debt burdens. Law schools may need to increase scholarships or other aid to support students who cannot secure private loans. Private lending has been minimal in legal education since 2006, when federal policy allowed graduate students to borrow up to the full cost of attendance, so there is uncertainty about how lenders will respond to renewed demand.Data show that about one-quarter of ABA-accredited law schools currently have average annual federal borrowing above the new $50,000 cap. At some elite institutions, graduates tend to earn high salaries, which may reassure private lenders. However, other schools with high borrowing levels report much lower median earnings, raising concerns about repayment risks. Experts warn that students at lower-ranked schools or from disadvantaged backgrounds could be hit hardest.In response, some schools are creating new financial strategies. The University of Kansas School of Law has launched an in-house loan program with a fixed 5% interest rate for borrowing above the cap. Santa Clara University School of Law is offering guaranteed scholarships to reduce tuition below the federal limit, and applications there have surged. Overall, the loan cap introduces financial uncertainty that could reshape enrollment decisions, access to legal education, and the long-term cost of becoming a lawyer.US law schools, students fear rising costs from new federal loan cap | ReutersThe U.S. Supreme Court has introduced new software designed to help identify potential conflicts of interest involving the justices. The tool will compare information about parties and attorneys in pending cases with financial and other disclosures maintained by each justice's chambers. These automated checks are intended to supplement, not replace, the justices' existing internal review process when deciding whether to step aside from a case.Under current practice, each of the nine justices independently determines whether recusal is necessary. The move comes after the Court adopted its first formal code of conduct in 2023, which states that a justice should withdraw when their impartiality could reasonably be questioned. Critics have pointed out that the code lacks an enforcement mechanism and leaves recusal decisions solely in the hands of the justices themselves.To support the new system, the Court is also strengthening filing requirements. Parties will need to provide more detailed disclosures, including fuller lists of involved entities and relevant stock ticker symbols. These updated requirements will take effect on March 16. Advocacy groups welcomed the technological upgrade as a step toward better ethics oversight, noting that similar conflict-checking systems have long been standard in lower federal courts.US Supreme Court adopts new technology to help identify conflicts of interest | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

The 2026 NWSL season is officially in sight! On today's episode of the Pride Pod, we're breaking down the Orlando Pride 2026 Preseason Schedule—including a heavy-hitting lineup of scrimmages against the Washington Spirit, Racing Louisville, and the 2025 Champions, Gotham FC.But the biggest headline? Luana. After a legendary return to form last season following her battle with Hodgkin's lymphoma, she has officially been called back up to the Brazilian National Team. We discuss what this means for our midfield anchor as she prepares for another dominant year in purple.Inside the Pride Pod:• Preseason Road Map: Dates and details for the February/March scrimmages at IMG Academy and beyond.• Seleção Return: Luana's call-up and how she's inspiring the global soccer community.• Fan Kickoff Events: "Pour Overs with Pride," the Secondary Kit launch, and "Pints with Pride" dates you need to know.• NWSL Blockbuster Trades: Why the league is reeling from the Croix Bethune and Claire Hutton moves.Don't forget to LIKE and SUBSCRIBE for the most authentic Orlando Pride coverage!#OrlandoPride #Luana #NWSL #OrlandoSoccer #BrazilWNT #NWSLPreseason #LoudAndProud #NWSL2026 #CroixBethune #WomenSoccer

  In this powerful episode of the Peak Human Labs Podcast, Dr. Sanjeev Goel sits down with ultra-endurance athlete, cancer survivor, and leadership speaker Sean Swarner to explore the intersection of resilience, identity, and purpose. Sean has accomplished feats most consider impossible, completing the Explorers Grand Slam, the Seven Summits plus the North and South Poles, running seven marathons on seven continents in seven days, finishing Ironman World Championships, and more, all while living with only one functioning lung. Sean shares his extraordinary journey through two childhood cancer diagnoses, Hodgkin's lymphoma at 13 and a rare sarcoma at 16, along with intensive chemotherapy, radiation that permanently damaged his right lung, and survival odds that were nearly nonexistent. Those early battles shaped the mindset he still lives by today, staying present, visualizing success, and anchoring his actions to deeper purpose. From imagining himself destroying cancer cells as a child to holding onto the image of a full family dinner table, Sean learned to focus not on avoiding death, but on choosing life. Together, Sean and Dr. Goel explore why the mind often quits before the body, how small acts of self-negotiation quietly erode core values, and why chasing external achievements can lead to hollow victories or even depression. Sean introduces the concept of “false summits”, milestones that look impressive but leave us asking, now what, and explains how true fulfillment comes from alignment, not accolades. Throughout the conversation, Sean offers practical and relatable tools for everyday life, breaking overwhelming goals into micro steps, reframing habits around who you are rather than what you're avoiding, and separating identity from accomplishments. He also shares insights from his upcoming book, The True Summit Method: How Leaders Turn Pressure into Peak Performance, and his work guiding others up Mount Kilimanjaro, where he blends extreme challenge with deep personal reflection. Whether you're navigating health challenges, pursuing big goals, rebuilding after burnout, or feeling unfulfilled despite success, this episode offers raw honesty, mental resilience strategies, and a grounded roadmap for building a life that feels both successful and meaningful, one intentional step at a time.   Our Guest: Sean Swarner Sean Swarner is an extreme endurance athlete, keynote speaker, author, and adventurer who defies limits. After surviving two childhood cancers that left him with one lung, he completed feats including the Explorers Grand Slam, seven marathons in seven days across seven continents, and multiple Ironman finishes. Featured in the documentary True North (available free on YouTube), Sean now helps leaders and adventurers avoid "false summits" through his True Summit Method framework, Kilimanjaro expeditions, workshops, and upcoming book. He blends personal experience with leadership insights to turn pressure into peak performance.   Key Takeaways Personal core values act as an internal compass during adversity and pressure. The mind often gives up before the body reaches its true limit. Small compromises with yourself can slowly erode confidence and self-respect. Focusing on the next small step makes overwhelming goals achievable. Achievement without alignment leads to false summits and emotional emptiness. True fulfillment comes from the process, not just the outcome. Success and fulfillment are not always the same; alignment bridges the gap. In This Episode: [00:00] Introduction [02:23] Sean's early life and cancer diagnoses [03:29] Impact of cancer and radiation on lung function [05:07] Coping with illness as a teenager [07:01] Second cancer diagnosis and emergency treatment [08:02] Mindset and visualization during illness [10:19] Family support and deeper purpose [13:11] Athletic recovery and mindset post-illness [14:06] Physiological limits and unique heart anatomy [15:03] The mind breaks before the body [16:18] Core values and self-negotiation [19:35] Techniques for endurance and goal setting [22:33] Applying mindset to everyday challenges [24:32] Identity, success, and fulfillment [26:20] Current mission and the true summit method [30:40] Conclusion and contact information   Resources and Links Peak Human Labs Website  LinkedIn  YouTube  Instagram  Podbean    Dr. Sanjeev Goel Website LinkedIn   Sean Swarner Website Instagram Book (upcoming): The True Summit Method: How Leaders Turn Pressure into Peak Performance Documentary: True North – The Sean Swarner  Story   

À 16 ans, Garance voit sa vie se fissurer sans comprendre pourquoi : une bosse dans le cou, une fatigue qui écrase, un corps qui envoie des signaux de plus en plus forts. Jusqu'à ce que le diagnostic tombe :Lymphome de Hodgkin, stade IV AB, pronostic vital engagé.Son corps est touché partout. Les traitements sont lourds, violents, épuisants. Puis vient la rémission… mais pas la fin du combat.Car l'après-cancer peut être une épreuve à part entière.Aujourd'hui, à 23 ans, Garance vit avec des séquelles physiques et émotionnelles intenses : douleurs nécessitant des antiépileptiques, blocages des jambes, perte de sensibilité, eczéma bullaire, malaises, fatigue chronique, anxiété, agoraphobie…Et pourtant, elle avance, avec une force bouleversante.Dans cet épisode, elle raconte :• la découverte de sa maladie,• les traitements, les douleurs, les paralysies,• l'impact social, scolaire, émotionnel,• la PMA à 19 ans pour préserver ses ovocytes,• la difficulté d'être crue, entendue, reconnue,• et cette résilience qu'on ne voit pas toujours derrière un visage jeune.Son témoignage met en lumière ce que la maladie laisse… même après.Ce qu'on ne dit pas assez. Ce qu'on minimise trop souvent.Un épisode intense, nécessaire.Un appel à écouter les corps, à croire les femmes, à ne jamais invalider les symptômes.Vous écoutez États Dames, le podcast au cœur de votre santé, pour toutes les femmes dont le corps et l'esprit ont été bouleversés.Excellente écoute.Garance : InstagramTiktok Youtube Stéphanie JaryInstagram FacebookHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

À 21 ans, Matéa ne s'attendait pas à ce que sa vie change aussi brutalement.Pendant des mois, son corps lui envoie des signaux qu'elle ne comprend pas encore :une fatigue inhabituelle, une toux persistante, des siestes qu'elle n'avait jamais faites,des proches qui s'inquiètent alors qu'elle, au fond, se persuade que tout va passer.Jusqu'au jour où la situation s'emballe.Des prises de sang inquiétantes, un passage par les urgences,et cette nuit d'hôpital où, seule devant son téléphone,elle découvre elle-même ce que personne ne lui a encore annoncé clairement :des mots qui font peur, un lymphome, un cancer du système lymphatique.Dans cet épisode, Matéa raconte son histoire avec une sincérité bouleversante.Elle parle de l'annonce, de l'errance, de cette sensation d'être jeune mais déjà épuisée.Elle évoque les réactions des autres, les mots qui blessent,les traitements, la perte de ses cheveux, son corps qui change,et le long chemin pour accepter, comprendre, traverser.Mais elle partage aussi la force qu'elle a trouvée en elle,les soutiens inattendus, les petites victoires qui l'ont portée,et cette maturité née au cœur de la tempête.Un témoignage qui rappelle à toutes les femmes une vérité essentielle :écouter son corps peut sauver une vie.

Élodie n'oubliera jamais ce moment.Une boule dans le cou. Une certitude que quelque chose cloche.Et quelques jours plus tard, le diagnostic tombe : lymphome de Hodgkin.Elle a 22 ans.Elle est infirmière, habituée à prendre soin des autres.Mais ce jour-là, tout s'inverse.Dans cet épisode, elle partage :le choc de l'annonce,les traitements lourds et leurs effets sur le corps,la rechute après des mois de combat,l'isolement en chambre stérile,et l'après… quand tout semble terminé, mais que rien n'est vraiment comme avant.

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

We would love to hear from you! Please share your thoughts or episode ideas at ⁠⁠⁠canceroutloud@cancercare.org⁠⁠⁠ or leave a comment on this episode!Please follow, rate and share Cancer Out Loud to help others find strength and support through our community.SummaryIn this episode of Cancer Care Out Loud, CancerCare Social Worker Hayley Feuchs speaks with Marija and her daughter Tara about their journey through a Hodgkin's lymphoma diagnosis and treatment. They discuss the challenges of diagnosis, the importance of advocating for yourself in the medical system, and the support they received from family, friends, and the community. Tara shares her experiences of maintaining normalcy during treatment, the emotional dynamics within their family, and the coping strategies that helped them navigate this difficult time. They also address misconceptions about cancer, the anxiety surrounding scans, and offer advice to families facing similar challenges.TakeawaysThe journey to diagnosis can be long and frustrating.Advocating for oneself is crucial in the medical system.Building a support network is essential for emotional health.Maintaining a routine can help create a sense of normalcy during treatment.Friends can provide unexpected support during difficult times.Family dynamics can shift, leading to closer relationships.Coping strategies can include humor and finding joy in small moments.Difficult conversations about cancer are often necessary but challenging.Misconceptions about cancer can lead to misunderstandings about the experience.Managing scanxiety is a common challenge for patients and caregivers.

"Radioimmunoconjugates work through a dual mechanism that combines immunologic targeting with localized radiation delivery. The monoclonal antibody components bind to specific tumor-associated antigens such as CD20, expressed on malignant B cells. Once found, the attached radioisotope delivers beta radiation directly to the tumor, causing DNA damage and cell death," Sabrina Enoch, MSN, RN, OCN®, CNMT, NMTCB (CT), theranostics clinical specialist at Highlands Oncology in Rogers, AR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radioimmunoconjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 30, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of radioimmunoconjugates in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles ONS Voice articles: Interprofessional Collaboration Reduces Time to Neutropenia Antibiotic Administration Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals Telehealth Has Value During Radiotherapy, Patients Say ONS Voice oncology drug reference sheets: Lutetium Lu 177 dotatate Lutetium Lu 177 vipivotide tetraxetan Radium 223 dichloride Sodium iodide-131 Strontium chloride Sr-89 ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiopharmaceutical Safety: Making It Easy Targeted Radionuclide Therapy: A Theranostic Approach to Cancer Therapy ONS Huddle Cards: Radiobiology Radiopharmaceuticals ONS Learning Libraries: Immuno-Oncology Radiation ONS Symptom Interventions for Prevention of Bleeding Drugs@FDA package inserts To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Radioimmunoconjugates are a specialized subset of radiopharmaceuticals designed to combine the specificity of monoclonal antibodies with the cytotoxic power of radiation. ... Early development focused on B-cell malignancies, particularly non-Hodgkin lymphoma." TS 1:51  "An important concept for nurses to understand is the crossfire effect, where radiation can affect nearby tumor cells, even though not every cell expressed has the target antigen. This helps explain why these agents can be effective even in heterogeneous tumors." TS 3:40 "At present, 90 Y-ibritumomab tiuxetan is the only radioimmunoconjugate approved by the U.S. Food and Drug Administration (FDA) in clinical use. Historically, iodine-131 tositumomab played a major role in establishing these therapy classes, but it's also useful to contrast radioimmunoconjugates with other radiopharmaceuticals, such as iodine-131 therapies, which a lot of places do at this time, used for thyroid diseases, or radium 223, used for metastatic prostate cancer. Unlike those agents, radioimmunoconjugates rely on antibody-mediated targeted rather than physiologic uptake or bone affinity." TS 4:55 "I just try to explain to [patients] that radiation exposure is like being next to a flame. The further you are away, the less heat you get, the less exposure you get. These patients can be radioactive for three days, seven days—it just depends on how fast they excrete it through their bodies with half-life exposure." TS 9:33 "While only one agent is currently approved, the principles established by radioimmunoconjugates continue to guide development for newer targeted radiopharmaceuticals. Emerging agents aim to improve targeting, reduce toxicity, and expand indications beyond hematologic malignancies. This evolution underscores the importance of nursing education in this rapidly changing field." TS 10:41 "Radioimmunoconjugates represent an important bridge between traditional oncology treatments and the future of targeted therapies. Oncology nurses play a vital role in ensuring safe delivery, patient understanding, and collaboration between multidisciplinary teams. So, it's very important to educate and also stay up to date on evidence-based practices." TS 13:12

Grief and Growth: Finding your way forward after loss w/Harriet Cabelly Harriet Cabelly has spent her career helping others find their way through life's most painful and difficult times.  Harrriet is a therapist, speaker and author who specializes in grief and positive living.  She's guided people through loss, major life challenges and changes and the road to rebuilding.Harriet faced her own grave challenge when she was diagnosed with non-Hodgkin's lymphoma in 2022. Sitting on both sides of the couch, Harriet brings a skillful integration of professional insights and personal stories.Links:https://www.rebuildlifenow.com/https://www.instagram.com/rebuildlifenow/Tags:Author,Cancer Survivor,Cancer Thriver,Grief,Mental Health,Positive Aging,Positive Psychology,Resiliency,Therapist,Wellbeing,Grief and Growth: Finding your way forward after loss w/Harriet Cabelly,Live Video Podcast Interview,Phantom Electric Ghost Podcast,PodcastSupport PEG by checking out our Sponsors:Download and use Newsly for free now from www.newsly.me or from the link in the description, and use promo code “GHOST” and receive a 1-month free premium subscription.The best tool for getting podcast guests:https://podmatch.com/signup/phantomelectricghostSubscribe to our Instagram for exclusive content:https://www.instagram.com/expansive_sound_experiments/Subscribe to our YouTube https://youtube.com/@phantomelectricghost?si=rEyT56WQvDsAoRprRSShttps://anchor.fm/s/3b31908/podcast/rssSubstackhttps://substack.com/@phantomelectricghost?utm_source=edit-profile-page

In today's episode, our discussion features Tycel Phillips, MD. Dr Phillips is an associate professor in the Department of Hematology and Hematopoietic Cell Transplantation in the Division of Lymphoma at City of Hope in Duarte, California.In our exclusive interview, Dr Phillips discussed updated efficacy and safety data from the phase 2 EPCORE NHL-1 trial (NCT03625037) investigating epcoritamab-bysp (Epkinly) monotherapy in patients with relapsed/refractory large B-cell lymphoma (LBCL). He noted that the data, which were presented at the 2025 ASH Annual Meeting, showed that several patients remained in response beyond 4 years, and that no new major safety signals were reported. Overall, he highlighted that the trial findings continue to support the use of epcoritamab as a third-line, potentially curative option for patients with LBCL. He also spotlighted the promise of synergistic polatuzumab vedotin-piiq (Polivy)–based combinations in the management of non-Hodgkin lymphoma.

In this powerful and deeply real conversation, Michelle Patidar shares her journey as a cancer survivor and health coach, reflecting on her diagnosis of non-Hodgkin's lymphoma at just 32 years old and the life-altering path that followed. Michelle opens up about the physical, emotional, and mental layers of healing — and how recovery goes far beyond treatment. From rebuilding her health through gut support and nutrition, to learning how unmanaged stress impacts the body, to the emotional work of therapy, journaling, and identity shifts after cancer. This episode is a grounded, honest look at what real healing looks like. Together, we explore how small, consistent habits can create massive change, why community and support matter so much after a diagnosis, and how allowing cancer to change you doesn't mean losing yourself...it can mean evolving into a stronger, more aligned version of who you're becoming. This episode is for anyone navigating life after cancer, supporting someone who is, or simply looking to live with more intention, health, and joy. Connect with Michelle here: https://www.instagram.com/revival.health.wellness/ Here is the probiotic she couldn't think of. It's by Just Thrive: https://a.co/d/dLopL5N and theotehr one is Seed probiotic: https://seed.com/?srsltid=AfmBOopVgjxvvGltFJNba1kk693B3V_oYJUUHOR9KPQLIP-KMoLUYE7F ____________________________________________________________________________  

#thePOZcast is proudly brought to you by Fountain - the leading enterprise platform for workforce management. Our platform enables companies to support their frontline workers from job application to departure. Fountain elevates the hiring, management, and retention of frontline workers at scale.To learn more, please visit: https://www.fountain.com/?utm_source=shrm-2024&utm_medium=event&utm_campaign=shrm-2024-podcast-adam-posner.Thanks for listening, and please follow us on Insta @NHPTalent and www.youtube.com/thePOZcastFor all episodes, please check out www.thePOZcast.com  Takeaways- The biggest misconception is that most people are excited about transformation.- A small percentage of the workforce drives the majority of results.- The top 20% of employees contribute to 80% of outcomes.- The top 1% can drive a quarter of the results.- Most employees are tied to their current work methods.- Transformation may not feel significant to the majority.- Business leaders often assume support without engagement.- Engaging employees is crucial for successful transformation.- There is often an under-investment in change management.- Leaders must facilitate change rather than just declare it. 00:00 – Welcome & Jeff's Backstory in HR TransformationAdam kicks off the POZcast and introduces Jeff Williams, president and CFO at Aptia, walking through his career leading massive HR and business transformation efforts at Paychex, ADP, Alight, Aon and more.01:13 – Growing Up With a Self-Made FatherJeff shares his family story: born Canadian, raised American, youngest of eight, and the journey of his dad going from drafting apprentice to CEO at the same company over 33 years—and the lessons embedded in that.02:35 – Early Lessons: Hard Work, Humor & LossJeff reflects on what he learned from his father before losing him at 19: the value of hard work, eating fast at a crowded table, and keeping humor and lightness at the center of life and leadership.03:45 – From Telecom to the People Business (ADP Entry Point)Jeff explains how he moved from technology and telecom into human capital, taking on the role leading ADP's Canadian operations and discovering the power of the HR and benefits space.04:38 – Hiring at a High Bar: Talent, Drive & InstinctsAdam asks how Jeff hired to ADP's level. Jeff lays out his hiring philosophy: ambition beyond natural gifts, complementary skills, people better than him in key areas—and why he trusts his instincts on fit.06:25 – Real Leadership: Hiring People Better Than YouThey dig into succession, “making yourself dispensable,” and the idea that if you can't take a vacation without everything falling apart, that's a failure of leadership, not a badge of honor.07:30 – Pre-Email Days & The Human Side of WorkJeff remembers the 286/386 era and talks about how, before digital tools, people invested more in each other in person—inside and outside of work—and how that shaped deeper relationships.08:43 – Remote Work, COVID, and an Isolated WorkforceThey go deep on the pandemic: the rapid shift home, the early productivity spike, inflation pressures, relocation, and the rise of isolation and mental health issues as remote work took hold.11:10 – Young Workers, Office Longing & Loyalty ShiftsAdam shares what he's seeing with candidates who actually want to be in-office to learn through osmosis. Jeff talks about building the next generation of leaders and how in-person time rebuilds fabric and loyalty.13:32 – Mental Health, Home Setups & Productivity RealityThey unpack the assumption that everyone has an ideal home workspace—calling out caregiving, cramped spaces, kids, and distractions—and how that's quietly driving some people back to the office.14:51 – Why Jeff Bet on Aptia & the Move to BostonJeff explains what drew him to Aptia: the chance to build something differentiated and lasting, formalize his cross-border life, and finally live and work in the same country as his family.17:42 – The Big Vision: Building the Best Benefits Company in AmericaJeff outlines his ambition to build the best (not necessarily biggest) benefits services and administration company—one loved by clients, employees, and partners while supporting the communities they serve.19:04 – Benefits as a Talent Magnet: Total Rewards, Not Just SalaryThey talk about smart candidates, how benefits (health, financial, time off, ancillary) close offers, and why companies need to position total rewards early and clearly in the hiring process.21:13 – Closing the Benefits Understanding GapJeff shares the reality: most employees don't fully understand or appreciate their benefits. He talks about accessibility, education, and surfacing value in ways employees actually grasp.22:33 – Introducing Aptia One: Seamless, AI-Led Benefits ExperienceJeff breaks down Aptia One—how it's designed to create simple, AI-led, consumer-grade experiences for employees, employers, and partners across phone, web, and natural language interfaces.25:14 – How Jeff Is Personally Upskilling in AIJeff shares his approach to AI as a leader: consuming everything he can, learning from experts, applying lessons from previous waves of tech disruption, and staying hyper-relevant to where markets are heading.26:54 – Realistic AI: Simplicity, Accuracy & Avoiding AI-WashingThey discuss using AI to simplify journeys, NOT over-hyping capabilities, and why, in a business where you must be nearly 100% accurate on benefits, you must apply AI carefully and responsibly.28:43 – The Hard Truth About TransformationJeff calls out a big misconception: leaders assume everyone's excited about transformation. He explains why frontline employees often aren't enlisted as deeply as leaders think and why change enablement is under-invested.30:18 – Service, Soul & Corporate PhilanthropyThe conversation shifts to service: Jeff's history with DEI, United Way, and community work, and why doing something for others makes him feel more complete as a human and leader.31:25 – Why People Want Companies With a SoulJeff explains how corporate philanthropy, whether via one flagship cause or hyper-local initiatives, shapes belonging, engagement, and the desire to work for companies that care about more than profit.33:55 – Jeff's Son's Cancer Journey & Life Perspective ShiftsJeff shares the powerful story of his son Kevin's osteosarcoma diagnosis at 13, the grueling treatment, and how that battle reshaped his view on perseverance, priorities, and what really matters.36:26 – Adam's Own Cancer Battle & Shared PerspectiveAdam opens up about his recent Hodgkin's lymphoma remission, the physical and emotional toll, and how surviving cancer reframes life, work, and gratitude for both of them.40:04 – What Keeps Jeff Up at Night: Stewardship & FamilyJeff talks about being a “work in progress,” how life is now about his kids, his wife, and his responsibilities, and the ongoing chase to be a good steward for his family, business, and community.41:48 – Optimism About Humanity & The Future of BenefitsJeff shares a global perspective: wherever he goes, people want similar things for their families and communities. He then lays out the “big three” of benefits—health, wealth, and time off—as core holdings.43:26 – Designing Benefits Like a PortfolioThey dig into tailoring benefits to your population (e.g., menopause benefits, pet insurance, nonprofit-oriented perks), feeding what works, starving what doesn't, and iterating to truly serve your people.44:37 – Redefining Success: Energy for the Journey AheadIn closing, Jeff defines success not by titles or money, but by whether you still wake up excited for what's ahead—at work, at home, on the golf course, and in life overall.46:08 – Wrap-Up & Where to Find Jeff and AptiaAdam closes the episode, sharing where listeners can learn more about Aptia, connect with Jeff on LinkedIn, and reminding everyone to review, subscribe, and keep being good to themselves and better to others.

BloodCancerTalks: ASH 2025 Lymphoma RoundupGuest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of RochesterAbstracts DiscussedFollicular LymphomaEPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FLTheme: Bispecific antibody combinations in R/R FL; comparing to other approaches Diffuse Large B-Cell Lymphoma (DLBCL) - Elderly/Unfit PatientsMorningSun (Sharman) - Mosunetuzumab monotherapy in patients ≥80 years or chemo-ineligibleEPCOR-DLBCL-3 (Vitolo) - Epcoritamab monotherapy in elderly patientsR-Pola-Glo - Rituximab-polatuzumab-glofitamab combination in older/frail patientsTheme: Single-agent and combination bispecific strategies for elderly and frail DLBCL patients DLBCL - First-Line TreatmentSMART STOP (Westin) - Chemotherapy-free approach using lenalidomide, tafasitamab, rituximab, acalabrutinib (ULTRA regimen)FrontMIND - Tafasitamab-lenalidomide added to R-CHOPTheme: Chemotherapy-sparing and chemo-intensification strategies in newly diagnosed DLBCL DLBCL - Relapsed/RefractoryDALY 2-EU (Borchmann) - Dual CD19/CD20 CAR-T (zamto-cel) versus R-GemOx in transplant-ineligible patientsTheme: Expanding CAR-T eligibility; treatment selection in transplant-ineligible R/R DLBCL Hodgkin LymphomaSWOG 1826 - 3-year update: Nivolumab-AVD versus brentuximab-AVDHD21 - 5-year update: PET-adapted BrECADD versus BEACOPPTheme: Long-term outcomes and treatment selection in newly diagnosed Hodgkin lymphoma Burkitt LymphomaZUMA-25 (Van Dorp) - Brexucabtagene autoleucel (Brexu-cel) in relapsed/refractory BurkittTheme: CAR-T therapy for the challenging population of R/R Burkitt lymphoma Mantle Cell Lymphoma - First-Line TrAVeRse - Acalabrutinib, venetoclax, rituximabGLOVe - Glofitamab, lenalidomide, venetoclax (high-risk MCL)BOVen - Zanubrutinib, obinutuzumab, venetoclax (older patients)MAVO - Acalabrutinib, venetoclax, obinutuzumabWindow-3 - Acalabrutinib-rituximab followed by brexu-cel (high-risk MCL)Theme: Chemotherapy-free combinations in newly diagnosed mantle cell lymphoma

When Bernie Lewinsky was a young radiotherapy resident, he studied under some of the most storied names in the field. Now, over fifty years later, he marvels at how much radiation oncology has changed. “You've gone from a betatron, cobalt and radium needles, and treating AP one day and PA the next, to probably treating on some sort of amazing [technology like a] TrueBeam or Elekta,” said Stacy Wentworth, a radiation oncologist at Duke University School of Medicine, who hosted this episode of the Cancer History Project Podcast.Lewinsky was one of the co-founders of the Endocurietherapy Society, which now exists as the American Brachytherapy Society. He has also helped develop the first group of freestanding radiation therapy clinics in Los Angeles, CA. Throughout the years—whether during his rotation at the Royal Marsden Hospital in London during residency or participating in tumor boards at UCLA—he has been part of many fervent debates with radiotherapy legends, arguing over whether Hodgkin's lymphoma spreads up or down the body, and the legitimacy of Intensity-Modulated Radiation Therapy in the early days. “Now it's so much more accurate, so much different and so precise,” Lewinsky said. “When you start talking about blocking the nodes in the heart to stop arrhythmias, we're very specific.”Lewinsky brings a treasure trove of artifacts to the interview—written orders of radium needles from 1948, an attachment that connected to an orthovoltage machine, a Mick applicator, and even a Bunsen burner. He plans to send some of these relics to the archives at ASTRO or the American College of Radiology. Beyond his practice of medicine, Lewinsky has also brought healing to his patients through his landscape photography. Some of his first photos captured an active volcano in El Salvador, where he grew up. Prints of some of his photographs can be found on the covers of academic journals and on the walls of his office. He distinctly remembers one patient, whose attention drifted off during an office visit. Lewinsky says the patient was struck by a photo of cherry blossoms he took in London.  “I said, ‘Wait a minute, what is it about that picture that's got you mesmerized?' and he says, ‘I remember when I was a little kid, my dad would take us cherry-picking. I sure wish my dad was here right now,” Lewinsky said. “It became my observation that there is a healing aspect to nature photography and putting it in the office when a patient is under tremendous stress, it not only calms the patient, but it brings back memories that they cherish.”A transcript of this interview is available at https://cancerhistoryproject.com/article/bernie-lewinsky-podcast/ 

Send us a textIn this powerful episode of Living the Dream with Curveball, we are joined by Edward Miskie, a remarkable author and 13-year survivor of a rare cancer. Edward shares his incredible journey, from his initial diagnosis of non-Hodgkin's lymphoma to his triumph over adversity. He discusses how his experiences reshaped his identity and fueled his passion for creativity, leading to the creation of the Remission Film Festival, set to launch in April 2026. This unique festival aims to spotlight the stories of creatives impacted by cancer while raising funds for Blood Cancer United. Edward also delves into his book, *Cancer Musical Theater and Other Chronic Illnesses*, blending humor and honesty to address the often overlooked challenges faced by cancer survivors. Listeners will be inspired by Edward's resilience, the importance of vulnerability in the arts, and the message that it's okay to redefine oneself after illness. Don't miss this enlightening discussion that encourages everyone to embrace their journey and support one another. For more information about Edward and his work, visit www.remissionfilmfest.comSupport the show

This episode of In The LOOP Podcast is one of the most raw and meaningful conversations we've shared — a story rooted in faith, resilience, and the power of community within the rodeo and equine industry.Inspired by 2025 World Champion Breakaway Roper Taylor Munsell, this episode brings awareness to Breakaway From Cancer and the real lives it has impacted. Jordan Jo sits down with cancer survivors Kacey Kobza and Lindsey Pender to share their journeys — not from a place of fear, but from courage, honesty, and hope.Kacey opens up about her diagnosis with Hodgkin's lymphoma, the overwhelming support she received from the rodeo community, and how that experience reshaped her perspective on life, competition, and relationships. Now cancer-free, she gives back as a board member of Breakaway From Cancer, helping lift financial and emotional burdens for others in the equine industry facing the same fight.Lindsey shares her ongoing battle with stage-three triple-negative breast cancer — from noticing early warning signs to navigating chemotherapy, surgery, motherhood, and faith. With vulnerability and strength, she speaks about trusting God in the unknown, accepting help, and staying present through each phase of treatment while continuing to show up for her family.This episode is not about cancer statistics or outcomes. It's about taking life one day at a time, refusing comparison, leaning on faith, and allowing community to carry you when you're tired. It's a reminder that in rodeo — and in life — no one fights alone. 

What do you do when you're told there's nothing left to be done and medicine cannot save you? For Diane Langlois, a terminal diagnosis of Stage 4 non-Hodgkin's lymphoma wasn't the end, it was the beginning of a 30-year journey into the power of the human spirit.In this episode, I sit down with Diane and discuss the moment she looked at her five young children and decided she wasn't going anywhere. Diane reminds us that we aren't broken machines in need of a mechanic, we are vibrant beings with an innate ability to heal. Join us for a conversation that will change the way you listen to your own body.Episode Highlights01:23 – The "Nothing More We Can Do" moment: Diane recounts her 1995 diagnosis of Stage 4 non-Hodgkin's lymphoma. She describes the chilling moment doctors told her there were no medical options left and sent her home to say her goodbyes.06:29 – Healing vs. Fixing Diane explains her core philosophy: the body isn't a machine that needs "fixing" by an external expert. Instead, it is a powerful system that, when given the right tools and lifestyle, has the innate ability to restore itself.08:27 – Tuning into the "Whispers" A lesson in body literacy. Diane explains that physical symptoms are not the body being "mean," but are actually "whispers" and cries for help that we must learn to listen to before they become "screams."10:51 – The Engine Light Analogy As a metaphor for modern medicine: taking a pill to mask a symptom is like putting a sticker over the "check engine" light in your car. Diane advocates for digging deeper to find the root cause.11:56 – The First Step: Two Minutes of Stillness For those overwhelmed by the idea of "healing," Diane offers a simple starting point: sitting in silence for just two minutes to reconnect the mind with the body.18:02 – The Healing Power of Sound: Diane discusses the science of frequency, explaining how simple acts like humming can stimulate the vagus nerve and increase nitric oxide levels to promote internal balance.23:55 – The Importance of "Your People" Diane emphasizes that healing doesn't happen in isolation. She discusses why finding a supportive, like-minded community is vital for emotional and physical recovery.Diane's Bio Diane Langlois is a Frequency Intuitive, Energetic Healing Guide and holistic wellness advocate devoted to helping women awaken their inner healer and reclaim radiant well-being. With over 30 years of experience in natural health, nutrition and energy medicine, she weaves ancient wisdom with modern resonance-based tools to support emotional balance, mental clarity and whole-body vitality. Through her Sound Sanctuary portals, intuitive scrolls, and signature seasonal offerings, Diane gently guides others back to themselves ~ one breath, one frequency, one remembrance at a time. Connect with Diane https://dianelanglois.ca/ https://www.facebook.com/dianelangloistcn https://www.linkedin.com/in/dianelangloistcn/ https://www.youtube.com/@HealingwithDeeAnne Who am I?Sarah Dawkins is a passionate Holistic Health and Healing Coach, international speaker and author of Heal Yourself. She's also a multi-award-winning entrepreneur and the award-winning host of the uplifting podcast Heal Yourself with Sarah Dawkins.With over 20 years' experience as a Registered Nurse, Sarah combines her deep understanding of conventional medicine with her own powerful self-healing journey to create a truly integrative approach. Having overcome multiple chronic health challenges herself, she now supports others in uncovering and addressing the root causes of their symptoms, helping them restore balance, reclaim their energy and create lasting, vibrant wellness.www.sarahdawkins.com#soundhealing #vibrationalmedicine #frequencyhealing #energyhealing #vagusnerve #soundtherapy #energeticmedicine #cancersurvivor #Stage4Survivor #healingjourney #overcomingtheodds #healingispossible #healthinspiration #miraclehealings

In this episode of Unlocked, Savannah Chrisley sits down with Whitney Haley for a conversation that's raw, funny, heartbreaking, and somehow still full of light. Whitney is a creator and storyteller whose life quite literally went viral when she shared her cancer diagnosis online at just 31 years old, six months postpartum. What followed was a whirlwind of stage four Hodgkin's lymphoma, aggressive chemo, motherhood, marriage strain, financial stress, and learning how to survive out loud.Whitney opens up about the moment she knew something was wrong, the symptoms doctors initially brushed off, and how trusting her gut ultimately saved her life. She talks candidly about losing her hair, navigating internet cruelty, and the mental toll cancer takes long after treatment ends. Along the way, she brings her signature humor, because if you can't laugh at chemo brain and a little chaos, what can you laugh at?But Whitney's story doesn't stop with cancer. She also shares her experience surviving an abusive first marriage, the strategic planning it took to leave safely, and why speaking openly about domestic violence matters more than ever. Her honesty has helped countless women find the courage to leave, heal, and start again.Now cancer free and focused on rebuilding her career and identity, Whitney is proof that resilience can be messy, loud, deeply human, and still powerful. This episode is a reminder that you're allowed to tell the truth about your life, even when it's uncomfortable, and that showing up as yourself might just change someone else's life too.Don't forget to like, subscribe, and hit the notification bell to stay updated on all our latest episodes!Thank you to our sponsors for supporting our show!- Booking.com: This episode of Unlocked is brought to you by Booking.com! There's something for everyone, so find exactly what you're booking for at https://www.booking.com! Booking.com, Booking.YEAH! Book today on the site or in the app!- Tempo: Tempo is offering my listeners 60% OFF your first box! Go to https://www.tempomeals.com/Unlocked to get yours today!- CBDISTILLERY: Get 25% OFF when you visit https://www.CBDistillery.com and use promo code UNLOCKED!- Rula: Use Rula to get affordable, high-quality therapy that's actually covered by insurance. Visit https://www.rula.com/Unlocked to get started. You deserve mental healthcare that works with you, not against your budget. #rulapod- Progressive: Join the over 28 million drivers who trust Progressive. Visit us at https://www.progressive.com! Thank you to Progressive for sponsoring the show! (Restrictions apply. Not available in all states and situations.)LET'S BE SOCIAL:Follow Savannah Chrisley:Insta: (https://www.instagram.com/SavannahChrisley)TikTok: (https://www.tiktok.com/@SavannahChrisley)X: (https://www.x.com/_itssavannah_)Follow Whitney Haley:Insta: (https://www.instagram.com/tennesseewhitney/)TikTok: (https://www.tiktok.com/@tennesseewhitney)Follow The Unlocked Podcast:Insta: (https://www.instagram.com/UnlockedWithSavannah)TikTok: (https://www.tiktok.com/@UnlockedWithSav)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In today's episode, Elizabeth sits down with Elissa Goodman, holistic nutritionist and cancer survivor, to explore the connection between stress, emotional health, and chronic illness. Elissa shares her story of being diagnosed with Hodgkin's lymphoma at 32 and the doctor who changed her life by asking a question no one else had. That moment sparked a mindset shift that became the foundation of her healing.She opens up about choosing a different path than fear-based treatment protocols, navigating cancer without chemotherapy, and realizing how chronic stress and emotional suppression had impacted her health long before her diagnosis. Elissa also reflects on the grief of later losing her husband to cancer, becoming a single mother, and how those experiences ultimately led her toward purpose-driven work. Together, they explore how nervous system regulation, emotional honesty, and self-belief support healing. They discuss why so many women live in a constant state of fight-or-flight and how perfectionism and people-pleasing can manifest physically in the body. Elissa shares her holistic approach to wellness, including food as nourishment, functional medicine, and peptides, and explains why true healing must address the mind, body, and spirit.Follow Elissa GoodmanWebsite: https://elissagoodman.comInstagram: https://www.instagram.com/elissagoodmanFollow usInstagram: https://www.instagram.com/thewellnessprocesspodTikTok: https://www.tiktok.com/@thewellnessprocessYouTube: https://www.youtube.com/@TheWellnessProcessSponsors:Use coupon code TWP to save 15% at boncharge.comStop putting off those doctors appointments and go to zocdoc.com/TWP to find and instantly book a doctor you love today.Redefine your standard of health. Secure 20% off your order and begin your intentional wellness journey today at piquelife.com/wellnessVisit carawayhome.com/TWP10 or use code TWP10 at checkout to take an additional 10% off your next purchase For a limited time to get 40% off your first box PLUS get a free item in every box for life at hungryroot.com/WELLNESSPROCESS and use code WELLNESSPROCESSUse code WELLLNESS at monarch.com for half off your first year.Produced by Dear MediaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL). Episode Highlights: ● EPCORE FL-1: the approval of Epcoritamab in combination with Rituximab and lenalidomide for relapsed refractory follicular lymphoma ● CLL-17: comparison between continuous BTK inhibitors and fixed-duration venetoclax with obinutuzumab ● BRUIN CLL-313: insights into the non-covalent BTK inhibitor, pirtobrutinib, and its effectiveness in the frontline setting compared to traditional treatments ● S1826: a three-year update on the use of Nivolumab-AVD versus BV-AVD in advanced-stage Hodgkin's lymphoma, showcasing improved PFS and better tolerability Join us as we unpack these practice-changing studies and discuss their implications for community oncologists. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more insights and highlights from oncology conferences! #ASH25 #Oncology #Hematology #Lymphoma #CLL #CancerResearch

How do scientists reason when they posit unobservables to explain their observed results? For example, how did Watson and Crick reason that DNA had a double-helix structure when they observed Franklin's image 51, or how did Hodgkin and Huxley reason that sodium ions carried the current flowing into the membrane of a voltage-clamped giant squid axon? In Compositional Abduction and Scientific Interpretation: A granular approach (Cambridge University Press), Kenneth Aizawa argues for an account of such reasoning as singular compositional abduction: explaining particular experimental results in terms of lower-level entities, such as the bonds between nucleotides or the positive charges of sodium ions. Aizawa, who is professor of philosophy at Rutgers University—Newark, draws on close examination of scientific practice to argue that dominant views in philosophy of science regarding abduction do not capture what scientists are actually doing. Instead, he articulates compositional abduction as a specific form of inferential practice in science distinct from eliminating alternative hypotheses, employing hypothetical-deductive confirmation, or identifying mechanism components. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

How do scientists reason when they posit unobservables to explain their observed results? For example, how did Watson and Crick reason that DNA had a double-helix structure when they observed Franklin's image 51, or how did Hodgkin and Huxley reason that sodium ions carried the current flowing into the membrane of a voltage-clamped giant squid axon? In Compositional Abduction and Scientific Interpretation: A granular approach (Cambridge University Press), Kenneth Aizawa argues for an account of such reasoning as singular compositional abduction: explaining particular experimental results in terms of lower-level entities, such as the bonds between nucleotides or the positive charges of sodium ions. Aizawa, who is professor of philosophy at Rutgers University—Newark, draws on close examination of scientific practice to argue that dominant views in philosophy of science regarding abduction do not capture what scientists are actually doing. Instead, he articulates compositional abduction as a specific form of inferential practice in science distinct from eliminating alternative hypotheses, employing hypothetical-deductive confirmation, or identifying mechanism components. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/philosophy

How do scientists reason when they posit unobservables to explain their observed results? For example, how did Watson and Crick reason that DNA had a double-helix structure when they observed Franklin's image 51, or how did Hodgkin and Huxley reason that sodium ions carried the current flowing into the membrane of a voltage-clamped giant squid axon? In Compositional Abduction and Scientific Interpretation: A granular approach (Cambridge University Press), Kenneth Aizawa argues for an account of such reasoning as singular compositional abduction: explaining particular experimental results in terms of lower-level entities, such as the bonds between nucleotides or the positive charges of sodium ions. Aizawa, who is professor of philosophy at Rutgers University—Newark, draws on close examination of scientific practice to argue that dominant views in philosophy of science regarding abduction do not capture what scientists are actually doing. Instead, he articulates compositional abduction as a specific form of inferential practice in science distinct from eliminating alternative hypotheses, employing hypothetical-deductive confirmation, or identifying mechanism components. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science

How do scientists reason when they posit unobservables to explain their observed results? For example, how did Watson and Crick reason that DNA had a double-helix structure when they observed Franklin's image 51, or how did Hodgkin and Huxley reason that sodium ions carried the current flowing into the membrane of a voltage-clamped giant squid axon? In Compositional Abduction and Scientific Interpretation: A granular approach (Cambridge University Press), Kenneth Aizawa argues for an account of such reasoning as singular compositional abduction: explaining particular experimental results in terms of lower-level entities, such as the bonds between nucleotides or the positive charges of sodium ions. Aizawa, who is professor of philosophy at Rutgers University—Newark, draws on close examination of scientific practice to argue that dominant views in philosophy of science regarding abduction do not capture what scientists are actually doing. Instead, he articulates compositional abduction as a specific form of inferential practice in science distinct from eliminating alternative hypotheses, employing hypothetical-deductive confirmation, or identifying mechanism components.

The lymphatic system, or lymphoid system, is one of the components of the circulatory system, and it serves a critical role in both immune function and surplus extracellular fluid drainage.  Components of the lymphatic system include lymph, lymphatic vessels and plexuses, lymph nodes, lymphatic cells, and a variety of lymphoid organs. The pattern and form of lymphatic channels are more variable and complex but generally parallel those of the peripheral vascular system. The lymphatic system partly functions to convey lymphatic fluid, or lymph, through a network of lymphatic channels, filter lymphatic fluid through lymph nodes and return lymphatic fluid to the bloodstream, where it is eventually eliminated. Nearly all body organs, regions, and systems have lymphatic channels to collect the various byproducts that require elimination . Liver and intestinal lymphatics produce about 80% of the volume of lymph in the body. Notable territories of the body that do not appear to contain lymphatics include the bone marrow, epidermis, as well as other tissues where blood vessels are absent. The central nervous system was long considered to be absent of lymphatic vessels until they were recently identified in the cranial meninges. Moreover, a vessel appearing to have lymphatic features was also discovered in the eye. The lymphatic system is critical in a clinical context, particularly given that it is a major route for cancer metastasis and that the inflammation of lymphatic vessels and lymph nodes is an indicator of pathology.  Structure The lymphatic system includes numerous structural components, including lymphatic capillaries, afferent lymphatic vessels, lymph nodes, efferent lymphatic vessels, and various lymphoid organs.  Lymphatic capillaries are tiny, thin-walled vessels that originate blindly within the extracellular space of various tissues. Lymphatic capillaries tend to be larger in diameter than blood capillaries and are interspersed among them to enhance their ability to collect interstitial fluid efficiently. They are critical in the drainage of extracellular fluid and allow this fluid to enter the closed capillaries but not exit due to their unique morphology. Lymphatic capillaries at their blind ends are composed of a thin endothelium without a basement membrane. The endothelial cells at the closed end of the capillary overlap but shift to open the capillary end when interstitial fluid pressure is greater than intra-capillary pressure. This process permits lymphocytes, interstitial fluid, bacteria, cellular debris, plasma proteins, and other cells to enter the lymphatic capillaries. Special lymphatic capillaries called lacteals exist in the small intestine to contribute to the absorption of dietary fats. Lymphatics in the liver contribute to a specialized role in transporting hepatic proteins into the bloodstream. The lymphatic capillaries of the body form large networks of channels called lymphatic plexuses and converge to form larger lymphatic vessels. Lymphatic vessels convey lymph, or lymphatic fluid, through their channels. Afferent (toward) lymphatic vessels convey unfiltered lymphatic fluid from the body tissues to the lymph nodes, and efferent (away) lymphatic vessels convey filtered lymphatic fluid from lymph nodes to subsequent lymph nodes or into the venous system. The various efferent lymphatic vessels in the body eventually converge to form two major lymphatic channels: the right lymphatic duct and the thoracic duct.  The right lymphatic duct drains most of the right upper quadrant of the body, including the right upper trunk, right upper extremity, and right head and neck. The right lymphatic trunk is a visible channel in the right cervical region just anterior to the anterior scalene muscle. Its origin and termination are variable in morphology, typically forming as the convergence of the right bronchomediastinal, jugular, and subclavian trunks, extending 1 to 2 centimeters in length before returning its contents to the systemic circulation at the junction of the right internal jugular, subclavian, and/or brachiocephalic veins.  The thoracic duct, also known as the left lymphatic duct or van Hoorne's canal, is the largest of the body's lymphatic channels. It drains most of the body except for the territory of the right superior thorax, head, neck, and upper extremity served by the right lymphatic duct. The thoracic duct is a thin-walled tubular vessel measuring 2 to 6 mm in diameter. The length of the duct ranges from 36 to 45 cm. The thoracic duct is highly variable in form but typically arises in the abdomen at the superior aspect of the cisterna chyli, around the level of the twelfth thoracic vertebra (T12). The cisterna chyli, from which it extends, is an expanded lymphatic sac that forms at the convergence of the intestinal and lumbar lymphatic trunks extending along the L1-L2 vertebral levels. The cisterna chyli is present in approximately 40-60% of the population, and in its absence, the intestinal and lumbar lymphatic trunks communicate directly with the thoracic duct at the T12 level. As a result, the thoracic duct receives lymphatic fluid from the lumbar lymphatic trunks and chyle, composed of lymphatic fluid and emulsified fats, from the intestinal lymphatic trunk. Initially, the thoracic duct is located just to the right of the midline and posterior to the aorta. It exits the abdomen and enters the thorax via the aortic hiatus formed by the right and left crura of the diaphragm, side by side with the aorta. The thoracic duct then ascends in the thoracic cavity just anterior and to the right of the vertebral column between the aorta and azygos vein. At about the level of the fifth thoracic vertebra (T5), the thoracic duct typically crosses to the left of the vertebral column and posterior to the esophagus. From here, it ascends vertically and usually empties its contents into the junction of the left subclavian and left internal jugular veins in the cervical region. To ensure that lymph does not flow backward, collecting lymphatic vessels and larger lymphatic vessels have one-way valves. These valves are not present in the lymphatic capillaries. These lymphatic valves permit the continued advancement of lymph through the lymphatic vessels aided by a pressure gradient created by vascular smooth muscle, skeletal muscle contraction, and respiratory movements. However, it is important to note that lymphatic vessels also communicate with the venous system through various anastomoses. Lymph nodes are small bean-shaped tissues situated along lymphatic vessels. Lymph nodes receive lymphatic fluid from afferent lymphatic vessels and convey lymph away through efferent lymphatic vessels. Lymph nodes serve as a filter and function to monitor lymphatic fluid/blood composition, drain excess tissue fluid and leaked plasma proteins, engulf pathogens, augment an immune response, and eradicate infection. Several organs in the body are considered to be lymphoid or lymphatic organs, given their role in the production of lymphocytes. These include the bone marrow, spleen, thymus, tonsils, lymph nodes, and other tissues. Lymphoid organs can be categorized as primary or secondary lymphoid organs. Primary lymphoid organs are those that produce lymphocytes, such as the bone marrow and thymus. Bone marrow is the primary site for the production of lymphocytes. The thymus is a glandular organ located anterior to the pericardium. It serves to mature and develop T cells, or thymus cell lymphocytes, in response to an inflammatory process or pathology. As individuals age, both their bone marrow and thymus reduce and accumulate fat. Secondary lymphoid organs serve as territories in which immune cells function and include the spleen, tonsils, lymph nodes, and various mucous membranes, such as in the intestines. The spleen is a purplish, fist-sized organ in the left upper abdominal quadrant that contributes to immune function by serving as a blood filter, storing lymphocytes within its white pulp, and being a site for an adaptive immune response to antigens. The lingual tonsils, palatine tonsils, and pharyngeal tonsils, or adenoids, work to prevent pathogens from entering the body. Mucous membranes in the gastrointestinal, respiratory, and genitourinary systems also function to prevent pathogens from entering the body. Lymph Lymphatic fluid, or lymph, is similar to blood plasma and tends to be watery, transparent, and yellowish in appearance. Extracellular fluid leaks out of the blood capillary walls because of pressure exerted by the heart or osmotic pressure at the cellular level. As the interstitial fluid accumulates, it is picked up by the tiny lymphatic capillaries along with other substances to form lymph. This fluid then passes through the lymphatic vessels and lymph nodes and finally enters the venous circulation. As the lymph passes through the lymph nodes, both monocytes and lymphocytes enter it.  Lymph is composed primarily of interstitial fluid with variable amounts of lymphocytes, bacteria, cellular debris, plasma proteins, and other cells. In the GI tract, lymphatic fluid is called chyle and has a milk-like appearance that is chiefly due to the presence of cholesterol, glycerol, fatty acids, and other fat products. The vessels that transport the lymphatic fluid from the GI tract are known as lacteals. Embryology The development of the lymphatic system is known from both human and animal, especially mouse studies. The lymphatic vessels form after the development of blood vessels, around six weeks post-fertilization. The endothelial cells that serve as precursors to the lymphatics arise from the embryonic cardinal veins. The process by which lymphatic vessels form is similar to that of the blood vessels and produces lymphatic-venous and intra-lymphatic anastomoses, but diverse origins exist for components of lymphatic vessel formation in different regions.  Six primary lymph sacs develop and are apparent about eight weeks post-fertilization. These include, from caudal to cranial, one cisterna chyli, one retroperitoneal lymph sac, two iliac lymph sacs, and two jugular lymph sacs. The jugular lymph sacs are the first to develop, initially appearing next to the jugular part of the cardinal vein. Lymphatic vessels then form adjacent to the blood vessels and connect the various lymph sacs. The lymphatic vessels primarily arise from the lymph sacs through the process of self-proliferation and polarized sprouting.  Stem/progenitor cells play a huge role in forming lymphatic tissues and vessels by contributing to sustained growth and postnatally differentiating into lymphatic endothelial cells. Lymphatic channels from the developing gut connect with the retroperitoneal lymph sac and the cisterna chyli, situated just posteriorly. The lymphatic channels of the lower extremities and inferior trunk communicate with the iliac lymph sacs. Finally, lymphatic channels in the head, neck and upper extremities drain to the jugular lymph sacs. Additionally, a right and left thoracic duct form and connect the cisterna chyli with the jugular lymph sacs and form anastomoses that eventually produce the typical adult form. The lymph sacs then produce groups of lymph nodes in the fetal period. Migrating mesenchyme enters the lymph sacs and produces lymphatic networks, connective tissue, and other layers of the lymph nodes. Function The lymphatic system's primary function is to balance the volume of interstitial fluid and convey it and excess protein molecules into the venous circulation. The lymphatic system is also important in immune surveillance, defending the body against foreign particles and microorganisms. It does so by conveying antigens and leukocytes to lymph nodes, where antigen-primed and targeted lymphocytes and other immune cells are conveyed into the lymphatic vessels and blood vessels. In addition, the system has a role in the absorption of fat-soluble vitamins and fatty substances in the gut via the gastrointestinal tract's lacteals within the villi and the transport of this material into the venous circulation.  Newly recognized lymphatic vessels are visible in the meninges relating to cerebrospinal fluid (CSF) outflow from the central nervous system. Finally, lymphatics may play a role in the clearance of ocular fluid via the lymphatic-like Schlemm canals. Clinical Significance Leaks of lymphatic fluid occur when the lymphatic vessels are damaged. In the abdomen, lymphatic vessel damage may occur during surgery, especially during retroperitoneal procedures such as repairing an abdominal aortic aneurysm. These leaks tend to be mild, and the vessels in the peritoneum and mesentery eventually absorb the lymphatic fluid or chyle. However, when the thoracic duct is injured in the chest, the chyle leak can be extensive. In most cases, conservative care with a no-fat diet (medium chain triglycerides) or total parenteral nutrition is unsuccessful. In most cases, if the injury to the thoracic duct was surgical, a surgical procedure is required to tie off the duct. If the thoracic duct is injured in the cervical region, then inserting a drainage tube and adopting a low-fat diet will help seal the leak. However, thoracic duct injury in the chest cavity usually requires drainage and surgery. It is rare for the thoracic segment of the thoracic duct to seal on its own. In terms of accumulation of chyle in the thorax (i.e., chylothorax), if a patient has an injury to the thoracic duct in the thorax below the T5 vertebral level, then fluid will collect in only the right pleural cavity. If the injury is to the thoracic duct in the thorax above the T5 vertebral level, then fluid will appear in both pleural cavities.   Other Issues The lymphatic system is prone to disorders like the venous and arterial circulatory systems. Developmental or functional defects of the lymphatic system cause lymphedema. When this occurs, the lymphatic system is unable to sufficiently drain lymphatic fluid resulting in its accumulation and swelling of the territory. Lymphedema, this swelling due to the accumulation of lymph, is classified as primary or secondary. Primary lymphedema is an inherited disorder where the lymphatic system development has been disrupted, causing absent or malformed lymphatic tissues. This condition often presents soon after birth, but some conditions may present later in life (e.g., at puberty or later adulthood). There are no effective treatments for primary lymphedema. Past surgical treatments were found to be mutilating and are no longer implemented. The present-day treatment revolves around compression stockings, pumps, and constrictive garments. Secondary lymphedema is an acquired disorder involving lymphatic system dysfunction that may result from many causes, including cancer, infection, trauma, or surgery. The treatment of secondary lymphedema depends on the cause. Oncological and other surgeries may result in secondary lymphedema due to the removal or biopsy of lymph nodes or lymphatic vessels. Non-surgical lymphedema may result from malignancies, obstruction within the lymphatic system, infection, or deep vein thrombosis. In most cases of obstructive secondary lymphedema, the drainage will resume if the inciting cause is removed, although some individuals may need to wear compressive stockings permanently. Also, physical therapy may help alleviate lymphedema when the extremities are involved. There is no absolute cure for lymphedema, but diagnosis and careful management can help to minimize complications. Lymphomas are cancers that arise from the cells of the lymphatic system. There are numerous types of lymphoma, but they are grouped into Hodgkin lymphoma and non-Hodgkin lymphoma. Lymphomas usually arise from the malignant transformation of specific lymphocytes in the lymphatic vessels or lymph nodes in the gastrointestinal tract, neck, axilla, or groin. Symptoms of lymphoma may include night sweats, fever, fatigue, itching, and weight loss. Cancers originating outside of the lymphatic system often spread via the lymphatic vessels and may involve regional lymph nodes serving the impacted organs or tissues. Lymphadenitis occurs when the lymph nodes become inflamed or enlarged. The cause is usually an adjacent bacterial infection but may also involve viruses or fungi. The lymph nodes usually enlarge and become tender. Lymphatic filariasis, or elephantiasis, is a very common mosquito-borne disorder caused by a parasite found in tropical and subtropical areas of the world, including Africa, Asia, the Pacific, the Caribbean, and South America. This condition involves parasitic microscopic nematodes (roundworms) that infect the lymphatic system and rapidly multiply and disrupt lymphatic function. Many infected individuals may have no outward symptoms, although the kidneys and lymphatic tissues may be damaged and dysfunctional. Symptomatic individuals may present with disfigurement caused by significant lymphedema and elephantiasis (thickening of the skin, particularly the extremities). The parasite may also cause hydrocele, an enlargement of the scrotum due to the accumulation of fluid, which may result from obstruction of the lymph nodes or vessels in the groin. Individuals presenting with symptoms have poorly draining lymphatics, often involving the extremities, resulting in huge extremities and marked disability. Lymphatic filariasis is the most common cause of disfigurement in the world, and it is the second most common cause of long-term disability.  (credits: NIH)

This epsiode is brought ot you by LMNT, Strong Coffee Company, Legion Athletics and Fatty15. After healing from Hodgkin's lymphoma in her 30s, Elissa Goodman turned her personal health crisis into a lifelong mission: helping others prevent and recover from cancer through holistic nutrition and mindful living. In this episode, she opens up about her journey from stress-driven corporate life to deep healing through green juicing, plant-based eating, and inner work like yoga, trauma release, and plant medicine. Elissa discusses how trauma, inflammation, and our toxic environment create the "cancer terrain"—and how we can reverse it with simple, nutrient-dense habits and radical self-love. Her story is not just about healing cancer but transforming one's entire way of living. Follow Elissa @elissagoodman Follow Chase @chase_chewning ----- 00:00 – The Current Cancer Epidemic 03:00 – Diagnosis at 32 & Discovering Juicing 07:00 – Taking Healing into Her Own Hands 11:00 – The Power of One Question: "Are You Happy?" 15:00 – Losing Her Husband & What Holistic Healing Taught Her 21:00 – Top Anti-Cancer Foods & The Inflammation Connection 28:00 - Cacao, Grief, and Plant Medicine as Emotional Healing Tools 33:00 - The Cancer Terrain: Internal Environment vs. Genetics 38:00 - Detoxification Basics: Sweat, Sleep, & Simplicity 43:00 - Myths About Juicing, Water Fasting, and Sugar ----- Episode resources: Get a FREE electrolyte variety mix with any purchase at https://www.DrinkLMNT.com/everforward Save 15% on organic coffee and lattes wiht code CHASE at https://www.StrongCoffeeCompany.com  Get an additional 15% off the 90-day starter kit of C15:0 essential fatty acids at https://www.Fatty15.com/everforward Get 20% off your entire first purhcase with code EVERFORWARD at https://www.LegionAthletics.com  Watch and subscribe on YouTube

This week Mike sits down with entrepreneur Chuck Cuda—a man who transformed a life-altering setback into a multimillion-dollar comeback. Chuck's journey begins with a single decision that landed him in prison after he refused to testify against friends in an illegal sports-betting case. But it was in a prison cell on Thanksgiving Day where he experienced the wake-up call that reshaped his entire life. From that moment, accountability became his superpower. Chuck rebuilt everything from the ground up. He went on to close over $200 million in commercial real estate deals, mastering the fundamentals of discipline, prospecting, and relationship-driven success. His ambition then carried him into the fast-evolving cannabis industry, where he expanded an operation from 5 to 22 licenses across three states—turning major financial challenges into profitability. Driven by purpose, Chuck also shares his passion for philanthropy, inspired by his father's battle with non-Hodgkin's lymphoma. Through the OPES Charitable Foundation, he has helped raise more than $3 million for cancer research. His daily affirmations, leadership philosophy, and belief in limitless potential offer a blueprint for anyone looking to rebuild their life or elevate their mindset.   IN THIS EPISODE:

A Espanya, la incid

Broadcast from KSQD, Santa Cruz on 12-11-2025: Dr. Dawn presents colleague Dr. Paul Godin's essay on why US healthcare fails as a market system . She explains that healthcare violates every assumption of functional markets: patients can't compare options during emergencies, information asymmetry prevents informed decisions, demand is inelastic when one has an urgent medical issue, and trust is essential to medicine and in direct conflict with profit incentives. Since 1988's Knox-Keen Act allowed for-profit healthcare, private equity has acquired and stripped hospitals, while administrative costs consume enormous resources fighting over payments rather than providing care. She contrasts this with European models like Switzerland and Germany where everyone must participate, insurers must accept all patients, and profit on basic coverage is limited. She celebrates a vaccination success story: HPV vaccines have reduced cervical cancer by 50% over 30 years. The American Cancer Society now endorses self-collected vaginal samples for HPV screening, with an FDA-approved at-home kit from Teal Health allowing women to skip speculums and traditional Pap smears. Current guidelines recommend screening starting at age 25, with testing every five years after a negative result. Dr. Dawn issues a health alert about multiple hospitalizations in Santa Cruz County from foraged wild mushrooms identified incorrectly by phone apps. She describes cholinergic toxicity symptoms: sweating, excessive salivation, pinpoint pupils, and abdominal cramping—signs requiring immediate emergency care rather than waiting it out. She offers follow-up vaccine advice: "go in wet, then sweat." Hydrate before vaccination, then take a hot Epsom salt bath until sweat runs off your face. This helps eliminate adjuvants that cause post-vaccine fatigue and aches, which are often misinterpreted as catching illness from the vaccine itself. Dr. Dawn expresses alarm that Kennedy's reconstituted ACIP nearly voted to eliminate hepatitis B vaccination at birth. She notes infants exposed to infected mothers have 99% infection rates, with half becoming chronically infected and half of those developing terminal cirrhosis or cancer. Testing pregnant women misses infections acquired during pregnancy, and 12-16% of delivering women have no test records. Major insurers have committed to covering birth vaccination through 2026 despite the panel's actions. She offers holiday microbiome advice from researcher Karen Corbin: increase fiber intake through steel-cut oats, whole grain breads like Dave's Killer Bread, beans, apples, and alternative pastas made from lentils or garbanzo beans. Cooking potatoes ahead and reheating creates resistant starch that feeds beneficial gut bacteria, reduces inflammation, and even stimulates natural GLP-1 production. Dr. Dawn reviews research proving health insurance saves lives. When the ACA's Medicaid expansion became optional by state, researchers could compare outcomes, finding 8% lower mortality and 19,000 fewer deaths in expansion states over four years. An accidental IRS experiment—sending insurance enrollment letters to only 85% of penalty payers—showed significantly lower mortality among those who subsequently got insured. Studies of gunshot and auto accident victims found uninsured patients died more often despite receiving identical emergency treatment. She concludes with surprising cancer symptoms: chest pain specifically triggered by alcohol consumption may indicate Hodgkin's lymphoma, as vasodilation activates inflammatory chemicals in affected lymph nodes. Fractures from minimal trauma in people without osteoporosis warrant investigation, as 5% of cancers involve bone. Elevated calcium levels double cancer diagnosis risk in the following year and should prompt follow-up testing.

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma. CME information and select publications here.

Dr. Alison Loren and Dr. Ann Partridge share the latest guideline from ASCO on the management of cancer during pregnancy. They highlight the importance of this multidisciplinary, evidence-based guideline and overarching principles for the management of cancer during pregnancy. Drs. Loren and Partridge discuss key recommendations from each section of the guideline, including diagnostic evaluation, oncologic management, obstetrical management, and psychological and social support. They also touch on the importance of this guideline and accompanying tools for clinicians and how this serves as a framework for pregnant patients with cancer. The conversation wraps up with a discussion on the unanswered questions and how future evidence will inform guideline updates.  Read the full guideline, "Management of Cancer During Pregnancy: ASCO Guideline" at www.asco.org/survivorship-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/survivorship-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-02115   Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Alison Loren from the Perelman School of Medicine of the University of Pennsylvania and Dr. Ann Partridge from Dana-Farber Cancer Institute, co-chairs on "Management of Cancer During Pregnancy: ASCO Guideline." Thank you for being here today, Dr. Loren and Dr. Partridge. Dr. Alison Loren: Thanks for having us. Dr. Ann Partridge: It's a pleasure. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Partridge and Dr. Loren who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the meat of this guideline, to start us off, Dr. Loren, could you provide an overview of the scope and purpose of this new guideline on the optimal management of cancer during pregnancy? Dr. Alison Loren: Sure, thanks, Brittany. So this was really born out of I think a lot of passion and concern for this really vulnerable patient population. We have observed, and I am sure it is not any surprise to your audience, that the incidence of cancer in young people is increasing. And simultaneously, people are choosing to become pregnant at older ages, and so we are seeing more and more people with a cancer diagnosis during their pregnancy. And for probably obvious reasons, there is really no way to do randomized clinical trials in this population. And so really trying to assemble and articulate the best evidence for safely managing the diagnosis of cancer, the management of cancer once it is confirmed, being thoughtful about obviously the health of the mom, but also attending to potential risks to the developing fetus, and really just trying to be really comprehensive and balanced about all the choices for these patients when they are facing some really challenging decisions in a very emotionally fraught environment. And I think it is really emotionally fraught for the providers, too. You know, this is obviously an extremely intense, very emotional set of decisions, and so trying to provide a rudder essentially to sort of help people frame the questions and trying to make as evidence-based a set of recommendations as possible. Dr. Ann Partridge: And I would just add that "evidence-based" is a strong word here because typically our, as you just heard, our gold standard evidence is a randomized trial, but you can't do that in this setting, in general. And so, what we were able to do with the support of the phenomenal ASCO staff was to pull together kind of the world's literature on the safety and outcomes of treatments during pregnancy, as well as consensus opinion. And I think that is a really, really critical difference about this particular guideline compared to many of the other ones that ASCO does, where consensus and good judgment needed to kind of rule the day when evidence is not available. So, there is a lot of that in our recommendations. Dr. Alison Loren: That is such a good point. And I just, before we move forward, I just want to reflect that the composition of the panel was really broad and wide-ranging. We had maternal medicine specialists, we had legal and ethical experts, we had representatives who understand pharmaceutical industries' perspectives, and then medical oncologists representing the full spectrum of oncology diagnoses. And so it was a really diverse, in terms of expertise, panel, internationally composed to try to really get the best consensus that we could in the absence of gold standard evidence. Brittany Harvey: Absolutely. That multidisciplinary panel is really key to developing this guideline and, as you said, looking at the evidence and even though it does not reach the level of randomized trials, still critically evaluating it and reviewing that along with consensus to come up with optimal management for diagnosis and management of cancer during pregnancy. So then to follow that up, I would like to next review the key recommendations of the guideline across the main sections that the expert panel provided. First, I will throw this out to either of you, but what are the important general principles for the management of cancer during pregnancy? Dr. Ann Partridge: I think there were three major principles that we hammer home in the guidelines. One is that this is a team sport. It is multidisciplinary care that is necessary in order to optimize outcomes for the patient and potentially for the fetus. And that you really need to, from the beginning, bring in a coordinated team, including not just oncologists but obstetricians, maternal-fetal medicine specialists, neonatologists, ethics consultants, and obviously the patient and potentially her family. So that, I think, is one of the most important things. Second would be that obviously in a pregnancy, there are two potential patients and that the nuances of safety and risk from treatment is really wrapped up in where in the trimester of the pregnancy the patient is diagnosed, along with the kind of cancer that it is, both the urgency of treatment and the risk of the cancer, as well as the potential risks of any given intervention across the cancer continuum. It is a broad guideline in that regard. And then finally, and this is particularly timely given what is going on from a sociopolitical standpoint in the U.S., really thinking about informed consent and potential ethical as well as legal implications of some of the choices that patients might have when they are thinking about, in particular, continuing a pregnancy or potential termination. Dr. Alison Loren: And I will just add that I think that the key to all of this guidance is nuance and individualization and also making sure that patients and their care providers understand all the choices that are available to them and also the consequences of those choices. You know, nobody would choose to receive chemotherapy during pregnancy if that wasn't necessary. So there are risks to treatment, but there are also risks to not treatment. And making sure that in a suboptimal situation where you do not have a lot of evidence, trying to weigh, the best you can, the risks and benefits of all of the choices so that the patient can come to a decision about the treatment plan that is right for her. Brittany Harvey: Definitely. And those core concepts really set the stage for individualized care on what is necessary for appropriate multidisciplinary care, prioritizing both patient autonomy and informed decision making. With those core concepts and key principles in mind, I would like to move into the recommendations section of the guideline. So what are the key recommendations regarding diagnostic evaluation for pregnant patients with signs or symptoms of cancer? Dr. Alison Loren: I think the most important thing is to not delay, that there are very careful and well-thought-out recommendations for how to evaluate a potential cancer. And while there are certain things that we know can be harmful, particularly when certain dose thresholds are exceeded - for instance, abdominal imaging, there are certain radiographic thresholds that you don't want to exceed because of risk of harm to the embryo or fetus - there are still lots of options for diagnosing cancer during pregnancy. And again, thinking about the costs of not doing versus the cost of doing, right? It is really important to make the diagnosis of cancer if that is a consideration or a concern. And sometimes going directly to biopsies or getting definitive studies, even if there is a small risk to the developing fetus, is really essential because if the mom does not survive, of course, the fetus is also not going to survive. And so we need to be thinking first about the patient who is sitting in front of us, the woman who needs to know what is going on in her body so she can make good decisions about her health. So, I think that is a key principle in thinking about this. Brittany Harvey: Absolutely. So, following that diagnosis of a new or recurrent cancer, what is recommended for oncologic management of patients who are diagnosed with cancer during their pregnancy? Dr. Ann Partridge: So, I think the general principle is, again, cancer is such a wide number of diseases and even within diseases, a range of stages and risks and associated opportunities for risk reduction and/or treatment depending on the type of cancer. Just by example, in the work that I do, which is breast cancer, once someone has had a surgery in the early-stage setting, a lot of our treatment is about risk reduction. And that is very different than from what Alison does, which is treating people with leukemia, where it is kind of binary. If you do not treat, including with cytotoxic drugs, the patient and an unborn fetus will die, especially early in the pregnancy, obviously. So this is where cancers are very, very different. So I think taking the approach of what would you do if the patient were not pregnant? And what is the best treatment for that particular patient with that particular kind of cancer? And then applying the pregnancy and where the patient is in that pregnancy in terms of the trimester of the pregnancy, and what is safe and what is unsafe from the options that you would give her if she were not pregnant. And then if the patient is choosing to keep the pregnancy, which in my practice, many people come and they come to me because they want to hold onto their pregnancy and want to figure out how to make it work, coming up with a regimen that tries to give them kind of the best bang for the buck, the best possible breast cancer therapy with the least harm, when possible, to the fetus. It is a bit of a balance, right? And then we cannot always give people the best approach. And sometimes it comes down to making a decision to give up something that may improve their survival so as not to harm the fetus. And sometimes it goes the opposite direction where a patient will say, "Oh, that is going to improve my survival by 5% and you can't give it to me now? I am going to choose to terminate." Even though that is obviously a very, very difficult and challenging decision to make in this setting because they want to optimize their survival and ideally live on to potentially have another pregnancy in the future if that is something that is of interest to her. So these are really, really hard conversations as you can imagine, but that is kind of where we go. Dr. Alison Loren: Yeah, and I think this is where the need for more research and understanding is really key because sometimes questions come up. I guess I am thinking about like HER2-directed agents, which we know are contraindicated in pregnancy. But what about sequencing? Does it matter when you get it? Can you get it later? I think that is something that we don't really fully understand. And similarly, again, this is obviously like a breast cancer and blood cancer focused discussion because that is what we do, but thinking about managing blood cancers, certainly with acute lymphoblastic leukemia, there is actually a lot of options now that, you know, you could potentially use to temporize or sort of get somebody through a pregnancy relatively safely. I am focusing on the word "relatively" because we do not know what the long-term impact might be of potentially not optimal therapy in the long run. And then thinking about other things like timing of a bone marrow transplant relative to either delivery or termination. I mean, again, we really do not know what are the right sets of sort of timing considerations for those. So there are just a lot of unknowns. And I think trying to be sort of self-aware and humble and honest about those unknowns so that the patient can engage in the conversation in a way that is meaningful to her and make the decisions that make the most sense for her. I think the most important thing is to make sure that the patient feels supported and safe to make those decisions with as little regret as possible. Brittany Harvey: Yes, I think it is really important that you mentioned that there is a wide range of cancers here, and that means that care really needs to be individualized for each patient. I will also note, just in this section, that I found really informative while reading through the guideline the list of oncologic agents that may be offered in each individual trimester, whether it is contraindicated or it can be used with caution, or if there is relatively good safety data on it for prioritizing maternal treatment needs and balancing fetal safety at the same time. I think that is, that is really key. And I think readers will really like that section of the guideline to provide concrete information for them and their patients. Dr. Alison Loren: Thank you. We actually spent a lot of time on that table and just thinking about what it should look like, what the format ought to be, what the language ought to be. Because of course, at the end of the day, everything should be used with caution. So what does that actually mean? And we sort of tried to explicate that a little bit in like the footnotes. We really tried to leverage what we know from clinical experience, from package labels, from mechanism of action to try to be as clear and definitive as we could be without overstating or understating what we know. Dr. Ann Partridge: Yeah, and I think we are focusing on breast and leukemia because that is what we do. But the truth is much of the data comes from those two areas. Leukemia, not because it is so common, but because you do not really have choices to treat or not treat. And so for decades, they have been treating and saying, "We hope the progeny comes out okay." And for many agents it does. The babies are okay. And so, we have reasonable observational data. And then in breast cancer, there have been actually some prospective registry-type studies where people have been followed and treated when pregnant, and the progeny have been accounted for, and so we have some good experience in that way too. Again, not randomized trials, but at least data that suggests certain agents are safe. And increasingly, because of that, when we have had to treat patients, we have said, "Okay, let us do it on this registry so that we can at least learn from every patient that comes in in this situation." And so, I think we will have more and more data given the growing number of young adults with cancer and the delays in childbearing that are happening around the world, and particularly in Westernized countries. I wish we did not. We wish we did not see this problem, but of course, when we do, we have to make sure that we learn from it and try and get patients enrolled in these registries and any kinds of studies that are available. Dr. Alison Loren: Yeah, I will just underscore that to say that, you know, there is outcomes of pregnancy and then there is outcomes of pregnancy, right? So there is like, "Okay, the baby was born with 10 fingers and 10 toes, and they passed their Apgar, and they are doing all their developmental processes along the way." But what happens when they are 10 or 15 or 20? Are they maturing normally? Are they cognitively intact? And then, of course, it is really inseparable from what is the impact on a family of having the mom with cancer? And how does that impact childhood development and intellectual development? And so these are really, really important questions that are very difficult to answer given the longitudinal information that you need, but it is a really critical question that, you know, patients ask and we do not know the answer. Dr. Ann Partridge: Yeah, that actually leads me to one of the important principles in the guideline that is a little bit of a change from when I first started practicing, which is we have learned from the wider neonatology literature, as they have followed up on the children that were born prematurely, that it is actually better not to be premature and to keep the baby in utero as long as it is safe for the fetus and the mother as long as possible, ideally to term rather than delivering early and then giving the chemo after that or separating the chemo from before and after. We used to try and deliver early and then give agents, but now we typically will give agents that are safe to be given at the end of pregnancy, ideally close to term, a couple weeks out, to allow for the ability of count recovery, and you do not want to go into preterm labor with chemotherapy on board, but we used to go much earlier and have an argument with our maternal-fetal medicine doctors. "How early can you get them out?" And they would say, "How long can they stay in?" And increasingly, we have been able to try and compromise to go even later and allow the fetus to go to term because of the neonatal outcomes that in longer term there is a suggestion that the children are developing better in the long run if they are kept in utero for as long as possible. Dr. Alison Loren: Yeah, that is such a great point. I think that is probably the most important thing for people to take away. For anyone who sort of does this, I mean, no one does this regularly because it is a rare event, although I think it is increasing as I mentioned. But this idea that the third trimester is, most of us know, is primarily a time for growth. Most of the critical development has already occurred, and so administering most chemotherapy agents towards the end of the third trimester seems to be preferable long term than delivering them early. So that is a really big change. I think we used to try to sort of, "Oh, get them to 30 or 32 weeks and then deliver," but we really are trying to get them closer to term, 37 weeks or more, and then coordinating the treatment so that they are not nadiring, as Ann said, at the time of planned delivery. Brittany Harvey: Yes, and that is a really important point related to evidence-based care and why we have changed that practice. And so then that actually leads nicely into my next question. But as you both mentioned, this is an important collaboration between oncologists and obstetricians. So the next section of the guideline addresses obstetrical practice. And so beyond what is standard, what additional recommendations are there in obstetrical management for pregnant patients with cancer? Dr. Alison Loren: That is a great question. So I will say we were really struggling with like how much do we cover? Like this is an oncology guideline. We are not obstetricians. We certainly had great representation from our maternal-fetal medicine colleagues on the panel. But really trying to sort of give useful information without overstepping. And so I think that the main recommendations are to increase the frequency of fetal monitoring, make sure that there is close attention to blood counts in the patient. But I think there is really still a gap in terms of what we know about optimal management of a pregnant person who is receiving therapy and how to handle the pregnancy itself. The delivery should be a usual delivery. Our colleagues did not recommend a planned C-section. They recommended usual care in terms of planning for the delivery. Obviously, if a C-section is indicated, then it should be done, but it should not be planned this way because of the cancer diagnosis. And I guess the other thing that we mentioned in the guideline, although we were reluctant to push it too hard because of access to these specialized services, was evaluating the placenta after birth to ensure that there were no metastases in the placenta itself. Dr. Ann Partridge: Those are the main things, and judicious and prudent obstetrical care, as I think, you know, is trying to be practiced regularly with MFM. Typically these patients should be followed not by your average OB/GYN, but a maternal-fetal medicine specialist because these patients will have special concerns, especially if they are sick. So oftentimes, especially Alison's patients, are actually sick with leukemia. And so you are monitoring them a lot, whereas, you know, a breast cancer patient typically isn't sick, although they could get sick with their chemotherapy. And so we really want to hand-in-hand manage these patients with our MFM colleagues. Dr. Alison Loren: I think we also highlighted in the guideline just for the refresher purposes of the oncology community, generally which drugs that would be given in a normal oncology setting are safe to be given to a pregnant person. So we talked a little bit about what kinds of steroids are recommended, antiemetics, DVT prophylaxis, peripartum. These are things that we think about a lot in oncology, but just want to make sure that it sort of intersected appropriately with the care of a pregnant patient. Brittany Harvey: Definitely. That specialized care is really important for patients who are pregnant and have cancer. And then the last section of the recommendations addresses psychological and social support. As you both mentioned before, this is a highly emotional time and it can be difficult and challenging to make decisions. So what is recommended for the psychological and social support of pregnant patients with cancer? Dr. Ann Partridge: Well, as I said, it is really something that needs to be considered at the beginning, through the diagnostic period, all the way into survivorship. Ironically, even though it is a highly fraught, emotional situation, I find that my pregnant patients actually are extraordinarily resilient, and what they are really focused on often is the safety of the fetus, because again, many of the people that come to me, it is a highly wanted pregnancy. They are also focused on their own health, of course, and often you need to bring in social work, sometimes a psychologist, professionals who are there just to help manage their emotions while we are focusing on what do they need medically to be as healthy as possible, both for the again, the mother, the patient, and the fetus. It is very tricky, and I will say also bringing in sometimes people on the ethics team in the hospital to help, both from the "Are you recommending and giving something that is safe?" That is number one. And then number two, sometimes patients want to be treated with drugs that we do not have any safety data for in pregnancy. What are our obligations? I think most of us would say we would not treat someone if we do not have safety data and there is suspicion for concern. But where is that line in terms of the right thing to do by that patient? And so we are all beholden to our ethics colleagues to help us when we make decisions like that. You know, we all want to do right by the patient, but we have to uphold our oaths and legal obligations. I don't know if you have to add on that because it's very tricky. Dr. Alison Loren: It is, it is very hard. I mean, I think, you know, there is a lot of emotion, obviously any cancer diagnosis is extremely charged and people are already at sort of a heightened, you know, they are anticipating a new baby and planning around that. And so it is just an extremely disruptive is the smallest word I can think of to describe it. And I think that often there is a co-parent, there might be parents and in-laws and other siblings, and then there is care after delivery. And so it is just a very complex set of dynamics. And having both our ethics colleagues and our psychology and social work colleagues to sort of just pitch in and make sure that the patient is being supported. I think there are sometimes really difficult situations where maybe what the patient wants is different from what the father of the baby wants or what the rest of the family wants. And so that can be really challenging. And you never really know where those landmines are going to pop up. So it is good to have the team on board early and often. Dr. Ann Partridge: Yeah, I would add to that, the other thing here that I think is really important, like in all of medicine but especially in situations like this, this is where we have to be very careful as professionals not to impose our own ethical, moral, emotional, personal views on the patient and to try to reserve judgment as much as possible. We are their navigator with the most important evidence and information that we can provide in the current situation. And that is where this guideline is extraordinarily helpful, we hope, for clinicians in the years to come. And at the same time, we cannot necessarily impose our own views and what we would do on a patient or what we tell our daughters, sisters, friends, family members. It is very tricky in that way. And so sometimes not just support for the patient, but support for the care team may be warranted in some of these very fraught situations. Dr. Alison Loren: Yeah, that is such a great point. And I was sort of thinking that too. I mean, it is, of course, the patient is front and center, but these are really difficult situations to navigate. And I will just add also that a lot of times these patients end up in academic centers, which I think is that's where the expertise or even just the experience may be. But the downside of that is that, you know, the teams are constantly changing. You have a new resident, you have a new intern, you have a new attending, a new fellow. And so, you know, the patients may be subjected to lots of different ways of communicating and sometimes those perceived differences can be really challenging. So sort of team huddles to sort of make sure that everybody is reading from the same script and everyone is comfortable with how the information is being presented so that the patient does not feel more confused or more overwhelmed, that they are kind of getting a consistent message from the whole team that, "This is what we know, this is what we are recommending, here are your other choices, and here are the pros and cons of each of these options." Brittany Harvey: Yes, I think you have both touched on this and that bringing in appropriate experts to support both clinicians and patients and their decision-making and their mental health is really important for this section of the guideline. We have already discussed this a fair bit throughout our conversation, but in your view, what is the importance of this guideline and how will it impact both clinicians and pregnant patients diagnosed with cancer? Dr. Ann Partridge: I could start with that. We just talked about experts and having them all around, but the fact is most people do not have the experts all around when they are dealing with this. And I think this is, you know, an expert-based, evidence-based guideline where having this in one's back pocket, whether you are in rural Montana or at a major cancer center on either coast, you will be armed with the latest and the greatest in terms of what we know and what we do not know, and some very helpful algorithms for how to think through the process of dealing with a patient who is diagnosed during pregnancy, whichever type of cancer it is. We could not cover every single specific thing about every cancer, although it is a pretty long guideline and there is a lot of nuance in there. So you might find a lot about specific cancers. And I think that that will be very, very helpful for people who are faced with this situation in the clinics just to frame it out, think through. Sometimes there is no answer that is the perfect answer and then, you know, using this as kind of a scaffolding and phoning a friend who may have more experience to help guide you and guide the patient, most importantly. I think it will be very helpful in that regard. Dr. Alison Loren: Yeah, I think so too. And I have talked about that we are working on this guideline and the anecdotal feedback has been, "This is so helpful." Like there really has not been, I think, an all-in-one place, diagnostic considerations, radiographic considerations, staging, treatment, all the modalities, surgical, radiation, systemic chemotherapy. We tried to include, when we could, novel agents including targeted agents and monoclonal antibodies and bispecifics and cellular immunotherapies and non-cellular immunotherapies. We really, really tried to cover in 2025 what are people using to treat cancer and to try to give the most balanced view of what we think is is safe or reasonably safe and what we think is either unproven or known to be risky, really to have it be kind of a go-to, like all-in-one, as much information as we have about these really challenging cases. We tried to include, Ann mentioned, you know, specific cancers, and I think when there were specific things to shout out with specific cancers, we really tried to highlight that. Like, "Okay, lots of young patients with cancer have Hodgkin's lymphoma, so what is safe and what is not for that specific case?" Or, "What is safe or what is not when you are thinking about colon cancers?" And we have a shout-out in here about considering checking for DPD deficiencies in patients who are pregnant. And I know it is generally recommended nowadays, but certainly for people who are pregnant, you know, you really want to avoid excess toxicity. So I think just really trying to be attentive to specifics about certain cancers in young patients and what would be valuable for a practicing oncologist and obstetrician to know when you are faced with this situation. Dr. Ann Partridge: Yeah, and I think the other critical thing that is great about this guideline is it's a starting place. And I anticipate that we will be building on this guideline for many years to come. And remember that when first, I was not around then, but probably three or four decades ago, when chemotherapy was just coming out and patients were coming in pregnant, there was a feeling I am sure that was, "We cannot give this to this person because it is purposefully going to destroy cells. And when you destroy cells in a growing fetus, you are going to destroy or harm that fetus." And yet, people did not have great choices. It was get treated or die, especially with things like leukemia early on. And bold patients along with their oncologist said, "Bring it on." And that is how some of this literature has been born. And so moving forward, there will be either purposeful exposures or inadvertent exposures of some of our therapies where we will learn ultimately. And this is a place where we can update these guidelines. That is the beautiful thing about the ASCO guidelines is that they are constantly being thought about to be updated. And then when there is enough of a change in practice, they will be updated such that they will continue to inform how we do this in the years to come for patients who come in pregnant. Dr. Allison Loren: Yeah, and I will say I have been doing this long enough now, we were just talking about a different guideline, the fertility guideline earlier today, and over the 20 years that the fertility guidelines have been out, just the amount of research has really skyrocketed. And you can see as you look at each guideline how much we have learned, what we can say, "Yes, this is working," "No, this is not working." Like, it is stuff that we used to say, "Oh, we do not really know," and now we have answers.  I think I speak for both of us when I say that we are hopeful that this will serve as, as Ann said, as a starting off point and really inspire people to ask the questions and do the research so that we can give better guidance moving forward, really trying to think about, you know, mechanisms and leaning on our colleagues in pharma and in the government who sort of think about safety and efficacy, to sort of make sure that they are contemplating not just non-pregnant patients, but also pregnant patients or as they are thinking about marking the package inserts with safety guidelines around this. Brittany Harvey: Yes, this is a critically important first guideline on the management of cancer during pregnancy, and we will look forward to continuing to build on that. I think as you mentioned, this guideline is far-reaching and has a lot of recommendations in it. And so both the full text of the guideline and those at-a-glance algorithms, figures, and tables will be really useful for clinicians in their clinic. Finally, to wrap us up, we have just been discussing this a little bit, but specifically, what are the outstanding questions on the management of pregnant patients with cancer, and where is this further research needed? Dr. Alison Loren: There are lots and lots and lots of unanswered questions. And I think if you look at the table, most of what we say is, "We are pretty sure this is okay, we are not so sure about this." I am paraphrasing, but we really just are operating in a paucity of what we would normally consider gold-standard evidence. It is hard to imagine, of course, there would ever be, as we mentioned in the beginning, randomized trials. But I think that preclinical data, mechanistic data, trying to think about including as we go through animal data, making sure that we are looking at female animals and pregnant animals so that we can sort of fully understand what the impact may be. And then I think thinking about more localized therapies around sort of radiation, you know, we are now moving into really hyper-focused radiation treatments like protons. Is that better because there is less scatter? Like I think those are real considerations that we just do not know the answer to. What do you think? Dr. Ann Partridge: I think so many unanswered questions, and this is a call to action to continue to and increase the documentation of the experiences and outcomes for patients diagnosed during pregnancy. Dr. Alison Loren: Yeah, and I think the long-term outcomes too are really going to be critical. Brittany Harvey: Yes, we will look forward to learning about more evidence across the spectrum of care to inform future updates to this guideline. So I want to thank you both so much for your work to develop this guideline, to review the extensive amounts of literature that you did, and work to create this guideline. And thank you also for your time today, Dr. Loren and Dr. Partridge. Dr. Alison Loren: Thanks. It was fun. Dr. Ann Partridge: Yeah, thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning into the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/survivorship-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. 

Featuring an interview with Dr Matthew Lunning, including the following topics: Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00) Overview of the CAR T-cell therapy administration process (4:40) Opportunities for referral for CAR T-cell therapy (10:05) Selection of a CAR T-cell therapy based on patient characteristics (16:09) Sequencing of CAR T-cell therapy for various non-Hodgkin lymphomas (23:23) Safety regulations and mitigation strategies for adverse events (30:36) Case: A woman in her early 80s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives lisocabtagene maraleucel (36:16) Case: A man in his early 60s with R/R mantle cell lymphoma receives brexucabtagene autoleucel (43:09) Case: A man in his early 60s with R/R multiple myeloma receives ciltacabtagene autoleucel (49:09) CME information and select publications

In this first half of a two-part conversation, I sit down with Jenny Leavitt — pastor's wife, author of GodPrints, and bereaved mom — to hear the story of her son, Jacob, and the unmistakable “GodPrints” woven throughout her family's journey.Jenny begins by describing her earlier battle with stage four non-Hodgkin's lymphoma while raising two very young boys, and how God used that season to prepare her heart in ways she wouldn't fully understand until years later. She then introduces us to Jacob — a friendly, artistic, big-hearted high school senior — and recounts the tragic accident caused by a drunk driver that took Jacob's life and left his older brother, Caleb, critically injured.Throughout the episode, Jenny speaks honestly about the physical, emotional, and spiritual shock of those early days, the challenge of grieving one child while caring for another, and the surprising places where God's fingerprints began to appear. She shares about a profound “GodPrint” uncovered just days after Jacob's death — a handwritten piece Jacob created months earlier that offered their family deep assurance of his salvation and his walk with the Lord.Jenny also offers compassionate, practical wisdom for newly bereaved parents: the importance of connection, the value of grace for yourself and others, and the reminder that you don't have to walk this path alone.Links Mentioned:GodPrints: Finding Evidence of God in the Shattered Pieces of Life by Jenny LeavittJenny's websiteResilient Hope resourcesBe sure to join us next week for Part Two, where Jenny reflects on how her grief has evolved over the last ten years, how she and her husband navigate grieving differently, and the GodPrints they continue to see in their story.I would love to hear your thoughts on the show. Click here to send me a message! (Though I read every message, I am unable to respond through this format.) ** IMPORTANT** - All views expressed by guests on this podcast are theirs alone, and may not represent the Statement of Faith and Statement of Beliefs of the While We're Waiting ministry. We'd love for you to connect with us here at While We're Waiting! Click HERE to visit our website and learn about our free While We're Waiting Weekends for bereaved parentsClick HERE to learn more about our network of While We're Waiting support groups all across the country. Click HERE to subscribe to our YouTube channelClick HERE to follow our public Facebook pageClick HERE to follow us on Instagram Click HERE to follow us on Twitter Click HERE to make a tax-deductible donation to the While We're Waiting ministryContact Jill by email at: jill@whilewerewaiting.org

Today's guest is Erin Cummings, co-founder and executive director of Hodgkin's International, a non-profit dedicated to supporting, educating, and advocating for long-term survivors of Hodgkin's Lymphoma Worldwide. She herself is an over 50 year survivor of Hodgkin's Lymphoma. Erin believes that survivorship is not the end of the cancer journey, but a lifelong chapter that deserves understanding, resources and hope.We talk all about Hodgkin's Lymphoma, treatments that are thankfully no longer in practice, what are called "late effects" of those treatments, the importance of survivorship care and community, pro-active health management, and so much more!!Resources:Erin's Website: https://www.hodgkinsinternational.com/Erin's Facebook:  https://www.facebook.com/hodgkinsurvivorsErin's Linkedin: https://www.linkedin.com/company/hodgkins-internationalErin's Instagram: https://www.instagram.com/hodgkinsinternational/Erin's Email: erincummings@hodgkinsinternational.orgFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

On this episode of Kankakee Podcast, host Drew Raisor sits down once again with Jeff Cross to talk about Ordinary Dads, a local group of about 15 fathers who come together each holiday season to sing Christmas music and raise money for families in need.Jeff shares the humble beginnings of the group, why “ordinary” is the point, and how a handful of dads with varying levels of musical ability create something meaningful through just eight practices a year. Drew and Jeff discuss the group's upcoming 2025 performances, the family-friendly atmosphere, and the joy — and humor — that comes from watching everyday dads step onstage in ugly sweaters to sing their hearts out.This year, Ordinary Dads is supporting two local families:• The Ericksons, whose young son Bedford has a rare neurological condition and needs accessible playground accommodations• The Dalton family, as their daughter Megan finishes treatment for non-Hodgkin's leukemiaJeff also talks about group growth, the challenges of scheduling dads, the thought behind not overcommitting the group, and how the community's support has led to standing-room-only shows.If you've ever wondered what can happen when everyday people come together with simple intentions and big hearts, this episode is for youSend us a textSupport the show

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Hodgkin vs. Non-Hodgkin Lymphoma⁠⁠⁠⁠⁠ from the Oncology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Sometimes we don’t get to choose when life asks us to begin again. One moment you’re following a dream, and the next you’re rebuilding from the pieces of what used to be. It’s a strange kind of starting over – the kind you never asked for but somehow learn to live inside. Ava Jones knows that space well. At seventeen, she survived a devastating car accident that took her father’s life and changed everything she knew about herself. Two years later, she was diagnosed with stage four cancer. Through it all, she’s learning what it means to keep moving, to ask for help, and to find gratitude even in the hardest chapters. This conversation isn’t about silver linings. It’s about choosing to live when the story doesn’t go the way you planned. Ava’s honesty reminds us that starting over doesn’t mean you’ve failed – it means you’re still here. What You’ll Hear The day Ava’s life changed forever Learning to walk, talk, and feel again after trauma Grieving her father while navigating recovery Letting go of the basketball dream that once defined her Facing cancer with honesty and faith in her support system Rediscovering joy in small, ordinary moments Listen to the full episode and more conversations like this at:

Support the show to get full episodes, full archive, and join the Discord community. The Transmitter is an online publication that aims to deliver useful information, insights and tools to build bridges across neuroscience and advance research. Visit thetransmitter.org to explore the latest neuroscience news and perspectives, written by journalists and scientists. Read more about our partnership. Sign up for Brain Inspired email alerts to be notified every time a new Brain Inspired episode is released. To explore more neuroscience news and perspectives, visit thetransmitter.org. Henk de Regt is a professor of Philosophy of Science and the director of the Institute for Science in Society at Radboud University. Henk wrote the book on Understanding. Literally, he wrote what has become a classic in philosophy of science, Understanding Scientific Understanding. Henks' account of understanding goes roughly like this, but you can learn more in his book and other writings. To claim you understand something in science requires that you can produce a theory-based explanation of whatever you claim to understand, and it depends on you having the right scientific skills to be able to work productively with that theory - for example, making qualitative predictions about it without performing calculations. So understanding is contextual and depends on the skills of the understander. There's more nuance to it, so like I said you should read the book, but this account of understanding distinguishes it from explanation itself, and distinguishes it from other accounts of understanding, which take understanding to be either a personal subjective sense - that feeling of something clicking in your mind - or simply the addition of more facts about something. In this conversation, we revisit Henk's work on understanding, and how it touches on many other topics, like realism, the use of metaphors, how public understanding differs from expert understanding, idealization and abstraction in science, and so on. And, because Henk's kind of understanding doesn't depend on subjective awareness or things being true, he and his cohorts have begun working on whether there could be a benchmark for degrees of understanding, to possibly asses whether AI demonstrates understanding, and to use as a common benchmark for humans and machines. Google Scholar page Social: @henkderegt.bsky.social;   Book: Understanding Scientific Understanding. Related papers Towards a benchmark for scientific understanding in humans and machines Metaphors as tools for understanding in science communication among experts and to the public Two scientific perspectives on nerve signal propagation: how incompatible approaches jointly promote progress in explanatory understanding 0:00 - Intro 10:13 - Philosophy of explanation vs understanding 14:32 - Different accounts of understanding 20:29 - Henk's account of understanding 26:47 - What counts as intelligible? 34:09 - Hodgkin and Huxley alternative 37:54 - Familiarity vs understanding 44:42 - Measuring understanding 1:02:53 - Machine understanding 1:16:39 - Non-factive understanding 1:23:34 - Abstraction vs understanding 1:31:07 - Public understanding of science 1:41:35 - Reflections on the book

Lucinda speaks with data protection expert Sarah Hodgkin-Bates about the critical overlap between HR and compliance, specifically regarding the handling of employee personal data.  They examine the importance of setting a company culture of transparency and cooperation by properly managing data protection, and discuss the legal frameworks governing data (GDPR/Data Protection Act 2018), how to manage access to different types of employee records (e.g., payroll vs. disciplinary), and the challenges organisations face with complex areas like Subject Access Requests (SARs) and the proper retention of sensitive data. KEY TAKEAWAYS Being transparent about how employee data is used, often via separate employee privacy notices, builds a positive, co-operative company culture and a better employee brand. A core principle of data protection is to minimise access. Access should only be given to individuals who strictly need it for their job or role (e.g., payroll staff, but not the whole accounts team). Subject Access Requests (SARs) are often raised during complaints to create stress. Organisations must have a clear procedure and recognise that a SAR must be fulfilled within one month, as failure to comply could lead to regulatory body involvement. Data protection classifies certain types of personal data (like protected characteristics under the Equality Act 2010 or biometric data from CCTV) as 'special category data,' requiring elevated security measures like encryption and limited access. BEST MOMENTS "If you get your data protection right, you are creating a spirit of transparency and cooperation." "A basic principle of data protection is to minimise access. So you would only give access to people that strictly need it for their job or role." "Subject Access Requests... are usually raised because someone has a complaint or a grievance and they're looking to gather evidence or to create stress and hassle." "If you are challenged by an employee, you must be able to give them an open and honest answer about how you're using your data and why you're using it." VALUABLE RESOURCES The HR Uprising Podcast | ⁠Apple⁠ | ⁠Spotify⁠ | ⁠Stitcher⁠   ⁠The HR Uprising LinkedIn Group⁠ ⁠How to Prioritise Self-Care (The HR Uprising)⁠ ⁠How To Be A Change Superhero - by Lucinda Carney⁠ HR Uprising Mastermind - ⁠https://hruprising.com/mastermind/⁠   ⁠www.changesuperhero.com⁠ ⁠www.hruprising.com⁠            Get your copy of How To Be A Change Superhero by emailing at ⁠info@actus.co.uk⁠ CONTACT SARAH LinkedIn - https://www.linkedin.com/in/sarah-hodgkin-bates-35a035177/ ABOUT THE HOST Lucinda Carney is a Business Psychologist with 15 years in Senior Corporate L&D roles and a further 10 as CEO of Actus Software where she worked closely with HR colleagues helping them to solve the same challenges across a huge range of industries. It was this breadth of experience that inspired Lucinda to set up the HR Uprising community to facilitate greater collaboration across HR professionals in different sectors, helping them to ‘rise up' together. “If you look up, you rise up” CONTACT METHOD Join the LinkedIn community - ⁠https://www.linkedin.com/groups/13714397/⁠ Email: ⁠Lucinda@advancechange.co.uk⁠ Linked In: ⁠https://www.linkedin.com/in/lucindacarney/⁠ Twitter: @lucindacarney Instagram: @hruprising Facebook: @hruprising This Podcast has been brought to you by Disruptive Media. ⁠https://disruptivemedia.co.uk/

Broadcast from KSQD, Santa Cruz on 11-13-2025: Dr. Dawn discusses a New England Journal of Medicine study examining radiation exposure from medical imaging in over 4 million children showing increased hematological cancer risk. Head and brain CTs deliver highest bone marrow doses, with under-1-year-olds receiving 20 milligrays compared to background radiation of 1 milligray yearly. The study found 3,000 cancers in 4 million children over roughly 10 years, with relative risk increasing 1.6-fold per CT scan. However, methodological flaws include combining US and Canadian cohorts with different data quality, potential reverse causation where imaging detected pre-existing cancers, and arbitrary 6-month latency assumptions are significant flaws in this study.. Despite small absolute risk increases given low baseline cancer rates, she encourages parents to question necessity of repeat scans and request alternatives like MRI when appropriate. She reports on cutting-edge CRISPR therapy using lipid nanoparticles to deliver molecular scissors targeting the ANGPTL3 gene controlling LDL cholesterol production. Recent setbacks in several other CRISPR trials raise issues for unexplained liver toxicity. Concerns include off-target gene editing effects and partially repaired DNA creating mutated proteins triggering autoimmune reactions. Dr. Dawn emphasizes restricting gene therapy to life-threatening genetic diseases with no alternatives until safety improves. Stanford scientists used AI model Evo trained on 9 trillion gene samples to design 300 new bacteriophages from scratch, with 16 phages successfully killing E. coli bacteria. AI tools now predict protein structures, design custom drugs, create antivenoms, invent antibiotics, and break down PFAS forever chemicals. The research represents evolution through computation and requires guardrails on AI's ability to manipulate biological structures. An emailer shares the Rosencare model where hotel chain owner Harris Rosen created self-insured health coverage featuring direct provider contracting, imaging facilities charging one-third to one-half traditional costs, transparent pharmacy benefit management, and zero or $5 primary care copays. Employees receive proactive screening for colonoscopies, mammograms, cholesterol, diabetes, and hypertension during clinic visits. Ninety percent of medicines including insulin cost nothing, with remaining drugs $0-25, and hospital admissions cost flat $750. The model saved $600 million while providing superior preventive care by eliminating insurance middlemen and focusing on early chronic disease detection when 75-85% of costs originate. Dr. Dawn explains abdominophrenic dyssynergia causing bloating unrelated to gas or food. The diaphragm descends and abdominal wall muscles relax, pushing organs forward after meals. CT scans showed lettuce-related bloating involved no intestinal gas changes but demonstrated this abnormal muscle reflex. Randomized trials showed biofeedback training with chest-lifting and abdominal wall contracting exercises before and after eating for four weeks improved symptoms 66%. She warns that constant bloating in postmenopausal women unrelated to eating requires ovarian cancer screening. She discusses how genes drive personality using dopamine receptor gene DRD4 polymorphisms as an example. The 7-repeat variant present in 48% of Americans creates receptors binding dopamine poorly, associating with ADHD, pathological gambling, alcoholism, drug dependence, and bulimia, plus personality traits of novelty-seeking, impulsiveness, and optimism. The 2-repeat DRD4 variant common in Asia correlates with lower anger and higher forgiveness. DRD2 variations enhance the memory of negative outcomes, creating pessimistic bias and avoidance behavior. She presents the KETO trial showing "lean mass hyper-responder phenotype" where very low-carbohydrate dieters averaging age 55 maintained LDL cholesterol of 272 for five years but showed identical coronary artery calcium scores and plaque burden as matched controls with LDL under 150. Despite extreme LDL elevation, the very low insulin levels from carbohydrate restriction prevent LDL oxidation, the inflammatory "loading" process enabling arterial damage. She concludes with unusual cancer symptom where recurrent pain in specific body locations after alcohol consumption, lasting 1-2 days, occurs in 5% of Hodgkin lymphoma patients and in other cancers when alcohol induced blood vessel dilation and inflammatory chemical release in cancer-containing lymph nodes causes pain after drinking.

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.

Fear thrives on vague labels; clarity starts with biology. We open by replacing the word “cancer” with “chronically fermenting cells,” so the focus shifts from doom to mechanism: cells favoring fermentation rather than oxidative phosphorylation. That reframe lets us explain PET scans and SUVs in plain language, showing how to distinguish metabolic activity from leftover anatomy, and why a smaller, quiet lesion can mean success even if it's still visible.From there, we build a full map of health that goes beyond any single protocol. Oral health emerges as a major, overlooked driver of systemic inflammation, making a visit to a true biological dentist a foundational step. We unpack environmental stressors—EMFs, persistent chemicals, ultra-processed food, and chronic sympathetic overdrive—that blunt immunity and confuse test results. On nutrition, we cut through the noise of diet wars and food myths, grounding choices in form-and-function design: eat to nourish and energize while reducing toxic load. Metabolic approaches make sense not as a fad but as measurable physiology, especially when tracked against baseline and follow-up imaging.We also tackle practical questions listeners ask every week. Parasites aren't just folklore; eggs, larvae, and adults respond to different agents, and the real goal is restoring balance so the body stops hosting trouble. For severe back pain, we highlight prolotherapy and prolozone as underused options that can stabilize and heal without the losses of fusion surgery. We walk through cases—Hodgkin's with lingering hot spots, pediatric brain tumors with urgent decisions, skin lesions mislabeled into aggressive plans—and show how to sequence actions, reduce fear, and choose comprehensively rather than experiment piecemeal.If you value honest guidance that puts mechanisms over buzzwords and measSend us a text Join Dr. Lodi's Inner Circle membership and unlock exclusive access to webinars, healthy recipes, e-books, educational videos, live Zoom Q&A sessions with Dr. Lodi, plus fresh content every month. Elevate your healing journey today by visiting drlodi.com and use the coupon code podcast (all lowercase: P-O-D-C-A-S-T) for 30% off your first month on any membership option. Support the showThis episode features answers to health and cancer-related questions from Dr. Lodi's social media livestream on Jan. 19th, 2025Join Dr. Lodi's FREE Q&A livestreams every Sunday on Facebook, Instagram, and Tiktok (@drthomaslodi) and listen to the replays here.Submit your question for next Sunday's Q&A Livestream here:https://drlodi.com/live/Facebookhttps://www.facebook.com/DrThomasLodi/Instagramhttps://www.instagram.com/drthomaslodi/ Join Dr. Lodi's Inner Circle membership and unlock exclusive access to webinars, healthy recipes, e-books, educational videos, live Zoom Q&A sessions with Dr. Lodi, plus fresh content every month. Elevate your healing journey today by visiting drlodi.com and use the coupon code podcast (all lowercase: P-O-D-C-A-S-T) for 30% off your first month on any membership option. Learn to Thrive with ADHD Podcast Welcome to the Learn to Thrive with ADHD Podcast. This is the show for you if you're... Listen on: Apple Podcasts Spotify Join Dr. Lodi's informative FREE Livestreams...

Episode: 00292 Released on November 10, 2025 Description: In this episode of Analyst Talk with Jason Elder, Jennifer Corum shares her remarkable 19 year journey with the Louisville Metro Police Department, including eight years as a crime analyst and her rise to Director of the Real Time Crime Center. From the early days of manually creating compstat maps to leading a 24/7 civilian staffed RTCC, Jennifer discusses how the field has evolved, the lessons she learned building a team from scratch, and how data and critical thinking drive modern policing. Jennifer also opens up about leading through 2020's social unrest, balancing motherhood, and surviving non Hodgkin's lymphoma, a battle that reshaped her perspective on leadership, gratitude, and the unseen strength of caretakers. She highlights the vital role her husband played throughout her recovery, emphasizing how support systems at home and work make resilience possible. This conversation is as much about courage and community as it is about crime analysis, and a must listen for anyone who believes in the people behind the data.

On this episode of Bringin' It Backwards, host Adam Lisicky reconnects with Caroline Grace Vein (Blondestandard) for an honest, inspiring conversation about resilience, creativity, and the journey of an artist. Nearly three years after her breakthrough debut "Blue Eyes," Caroline opens up about navigating health challenges—including a diagnosis of Hodgkin's lymphoma just after graduating college—and how they shaped her music and perspective. She shares how those experiences led to a deeper, more authentic songwriting process, the evolution of her sound from bubblegum pop to alternative rock, and the impact of community and collaboration in her work. Caroline dives into the stories behind new singles like "California Dreams," "Freaking Out," "Ruin My Day," and her latest release, "Arms of Another," offering insight into the themes of vulnerability, strength, and connection that drive her artistry. Plus, Caroline reveals she's working on a new podcast to share her story even further, and gives advice to fellow aspiring musicians: stay true to yourself, focus on what you love, and let your art resonate authentically. Whether you're an indie musician, a fan of genuine artist stories, or looking for inspiration to overcome obstacles and pursue your passion, this episode is full of raw, empowering moments you won't want to miss. Listen to the full interview and be sure to subscribe to Bringin' It Backwards for more stories from legendary and rising artists!